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 Our inability to efficiently target and eliminate the latent reservoir remains the biggest 
barrier to a cure to HIV/AIDS. Accordingly, there exist several ongoing efforts to not only 
understand the reservoir in varied patient groups, but also to determine an efficient means to 
achieve either a functional or a sterilizing cure. To this end, several trials are underway with the 
shock-and-kill strategy remaining the most clinically advanced. Shock-and-kill employs the use of 
small pharmacological molecules termed latency reversing agents (LRAs) to reverse latency with 
two goals in mind. First, to transcriptionally activate latent reservoir cells so that their subsequent 
production of viral proteins renders them visible to the immune system for targeted elimination 
and second to achieve this in the presence of antiretroviral therapy (ART) so as to prevent new 
rounds of infection.  
 Despite the allure of the shock-and-kill strategy, there has been no evidence to date of an 
ability of this strategy to reduce the size of the latent reservoir. One reason that shock-and-kill 
trials continue to fail to show significant reductions in the latent reservoir may be the inability of 
poorly functioning chronic progressor (CP- control HIV with ART) immune effector cells to 
effectively target and eliminate reactivated reservoir cells. While this may arise from pre-existing 
immune exhaustion, it is possible that the LRAs employed may themselves contribute to immune 
impairment. Consequently, enhancing the antiviral activity of effector cells might improve the 
effectiveness of shock-and-kill trials and may also enhance other therapeutic strategies aimed at 
eliminating the latent reservoir. Outside of shock-and-kill strategies however, other avenues exist 
to attain a functional cure of HIV/AIDS. In particular, given that elite suppressors (ES- control 
HIV without ART) control viral replication without therapy, they represent a model of a functional 




elite control, characterizing the frequency of latently infected CD4+ T cells in ES may shed light 
on the reservoir size needed to attain a functional cure, with or without shock-and-kill strategies.  
 We address each of these questions in this thesis write-up. Specifically, in chapter one, we 
assess the size of the inducible reservoir in ES to better understand what the latent reservoir in a 
functional cure might look like. Among other findings, our data demonstrates that despite the fact 
that most ES have markedly small reservoirs compared to CP, a small reservoir size may not be a 
requirement for attaining a functional cure. In chapter two, we tackle the shock-and-kill strategy 
to better understand if the LRA ingenol-B has any adverse effects on the HIV suppressive immune 
function of ES CD8+ T cells. We observe that while ingenol-B on its own has no adverse effects 
on ES CD8+ T cell HIV suppressive capacity, the combination of ingenol with another LRA, JQ1, 
inhibits the HIV specific suppressive capacity of CD8+ T cells in a dose dependent manner. 
Finally, in our effort to enhance the antiviral capacity of CP effector cells for the control of HIV 
infection, we explore the potential of using short course treatments of the type-1 interferon, IFN-
α, to enhance NK cell immune function in ES and CP without inhibiting similar responses in 
patient CD8+ T cells. Our findings demonstrate that short course treatments of IFN-α not only 
enhance the HIV suppressive capacities of progressor and non-progressor NK cells, but achieve 
this while also enhancing the antiviral capacity of patient CD8+ T cells. Overall, our data have 
significant implications for the cure agenda.  
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1.1 A BRIEF INTRODUCTION TO HIV/AIDS  
Human Immunodeficiency Virus (HIV) is the causative agent for the Acquired 
Immunodeficiency Syndrome (AIDS). There are two types: HIV-1 and HIV-2 (GAC, 2016). 
Although HIV-1 is clinically similar to HIV-2, the two viruses are genetically distinct with HIV-
2 being predominant in West Africa and exhibiting a slower disease pathogenesis and progression 
to AIDS than HIV-1 (Visseaux et al, 2016). Despite these differences, both viruses infect target 
cells expressing the CD4 receptor (required for entry). These include, mainly, CD4+ T cells, as 
well as macrophages, dendritic cells and astrocytes (GAC, 2016). Furthermore, depending on the 
tropism of the virus, the co-receptors CCR5 (the natural receptor for several chemokines including 
MIP-1 beta and RANTES) or CXCR4 (the natural receptor for the chemokine SDF-1) are also 
utilized. Specifically, the virus is termed R5 tropic when the CCR5 receptor is used, and X4 tropic 
when CXCR4 is used (GAC, 2016). Upon initial infection with either virus type, the immune 
response attempts to control and suppress viral replication. However, for numerous reasons 
touched upon in subsequent paragraphs, this control is not complete and over time, the chronic 
presence of the infection leads to death of the (main) target cells. This death is mediated by both 
apoptotic viral cytopathic effects and the pyropoptosis of non-productively infected cells (Doitsh 
et al, 2014). Ultimately, large scale death, with disproportionate rates of replacement of target 
CD4+ T cells, leads to unhealthy reductions with less than < 200 cells/ul of blood leading to the 






Figure 1. Viral load and CD4+ T cell counts from infection to AIDS. At primary infection, HIV viral loads rapidly rise within 
the first 3 weeks. In subsequent weeks, this replication is quickly controlled by antiviral immune responses leading to a drop in 
viremia to set point. Over time, and in the absence of ART, viral replication steadily continues, gradually depleting CD4+ T cells. 
While variable from patient to patient, ultimately the loss of CD4+ T cell allows susceptibility to opportunistic infections which, 
in the absence of a strong immune response leads to AIDS and if still untreated, death. Adapted from Tirado-Ramos et al, 2010. 
 
It is worth noting that while all of this thesis work is focused on HIV-1 (clade and tropisms 
used will be clarified in subsequent methodologies), it is our understanding of both types of HIV 
that has fueled our progress in the HIV/AIDS therapeutics arena. In this regard, the most critical 
advancement has been the generation of several kinds of effective antiretroviral therapies (ART). 
Existing in 7 classes with several new drugs in the pipeline (Gravatt et al, 2017), combinatorial 
ART is capable of reducing viral loads to below limits of detection by standard assays (less than 
20 copies of HIV mRNA per ml of plasma). However, because ART bars replication, but does not 
eliminate viral particles, it must be taken daily, for life. While this might come with challenges 
including adherence and (potentially) undesirable side effects, for most individuals (termed 
chronic progressors, CP), there are no other alternatives. In addition to CP, however, other groups 






group, termed long term non-progressors (LTNP) is able to control HIV-1 infections without 
therapy and maintain CD4+ T cell counts above 500 cells/ul of blood for about 5-7 years before 
ultimately losing control (Grabar et al, 2017, Okulicz and Olivier, 2011). A different group of 
patients, called elite controllers or suppressors (ES), spontaneously control viral replication to 
below the limits of detection of clinical assays for extended periods of time without therapy or 
clinical signs of disease progression (Blankson, 2010).  
 
1.2 HIV ELITE CONTROLLERS/SUPPRESSORS  
As might be expected, ES are a very rare group of HIV infected individuals. Representing 
only about 1% of all HIV infected subjects (Okulicz and Olivier, 2011), their unique ability for 
spontaneous control without therapy has inspired many studies, conducted to understand how they 
achieve this and if this control can be recapitulated. To date, we have no single explanation for the 
phenomenon of elite suppression. While some studies have demonstrated that what might have 
been considered elite control was actually infection with defective viruses (Calugi et al, 2006, 
Yamada and Iwamoto, 2000, Deacon et al, 1995), many other studies have demonstrated infection 
with replication competent viruses (Salgado et al, 2014, Buckheit III et al, 2012, Blankson et al, 
2007) and even transmission amongst discordant couples where a CP passes on their virus to a 
partner who then becomes an ES (Buckheit III et al, 2012, Bailey et al, 2008). To date, elite 
suppression has been associated with several factors, including immunogenetics such as having 
HLA-B*57 and HLA-B*27 (Martin and Carrington, 2014), cellular CD8+ T cell adaptive immune 
responses (Altfeld et al, 2006, Betts et al, 2006, Migueles et al, 2000), and innate immune 




Despite these unique characteristics, it is important to note that while viral replication is 
undetectable by standard assays in ES, it is not absent. Data have shown that there is in fact an 
evolution of plasma viremia amongst these patients- a phenomenon that cannot occur in the 
absence of active replication (O’Connell, 2010). As such, ES do not represent a sterilizing cure 
where virus is completely eliminated, but rather a functional one, where the virus is persistent, but 
does not cause disease, as in most cases of varicella zoster virus (VZV) or herpes simplex virus 
(HSV) infections. In the examples of VZV and HSV, the infection is considered ‘functionally’ 
cured because in the absence of any medication, a quiescent latent state of infection allows the 
virus to persist in its host without (for the most part) causing disease. Nevertheless, with the 
reactivation of HSV or VZV, cold sores or shingles, respectively, is possible (Kennedy et al, 2015).  
HIV, like the afore mentioned examples, also establishes latency (Siliciano and Greene, 
2011). A stochastic event, it is thought to occur when the infected CD4+ T cell transitions into a 
resting memory state with a virus stably integrated into its genome as a provirus (Murray 2016). 
Many resting memory cells also harbor defective viruses. As such, it is the inducible reservoir, 
harboring intact proviruses capable of yielding productive infections with latency reversal and 
virus reactivation (Figure 2) that serves as the barrier to an HIV cure (Bruner et al, 2019, Siliciano 
and Greene, 2011, Chun et al 1997). Usually, in the absence of CD4+ T cell activation, latent 
reservoir proviruses are mostly quiescent. When the reservoir cells are activated however, trace 
levels of viremia occur. This low level viremia does not lead to ongoing viral replication due to 
the presence of ART (Siliciano and Greene, 2011, Bailey et al, 2006). In the absence of ART 
however, for instance in the event of treatment interruption, the same residual viremia is capable 
of establishing new rounds of infection and, by extension, expanding the reservoir. This occurs 




(Pinkevych et al, 2019). In addition to ART interruption, the fact that these memory CD4+ T cell 
latent reservoirs can be expanded clonally, either by homeostatic proliferation (Hosmane et al, 
2017) or possibly antigen stimulation (Mendoza et al, 2020, Wang et al, 2018, Simonetti et al, 
2015), and that myeloid derived macrophages might also contribute as a latent reservoir of their 
own (Abreu et al, 2019, Wong et al, 2019), only serves to further complicate the challenge of 
potentially eliminating this reservoir.  
If we can understand and eliminate latent HIV, then we could potentially cure HIV/AIDS. 
Barring this, the next best option is to understand how to control and/reduce the size of the 
reservoir, and to achieve this to the point where any viral rebound can be controlled by the immune 
system so that the virus does not cause disease in the absence therapy. If this can be achieved 
(particularly in CP), then a functional cure would have been achieved. Yet, this is actually quite a 
challenge because data suggest that in people destined to be progressors, no matter how early 
therapy is initiated and how small the initial reservoir is, disease inducing rebound is inevitable 
(Pinkevych et al, 2019, Heinrich, 2017, Persaud, 2013). Despite these data, the impetus for trying 
rests in two facts. First, mathematical modeling from existing case reports suggests that greater 
than 3.5 log reduction in viral reservoir size might be needed for an ART free remission with fewer 
logs extending, but not eliminating, the time to rebound (Hill et al, 2016). The second (and more 






Figure 2. The establishment of latent reservoirs in resting CD4+ T cells. After antigen presentation, most activated CD4+ T 
cells die with a few remaining as memory sentinels (top boxed pane). In the event of HIV infection and HIV latency establishment, 
the activated, infected, CD4+ T cells also die (bottom left brown panel of cells). Some activated CD4+ T cells transitioning to a 
state of rest may be infected with the virus and transition with the provirus stably integrated into its genome (right hand green panel 
of cells). If this latent infection is with a provirus capable of being induced and producing new, replication competent virions, then 
this latently infected cell is considered part of a reservoir. These comprise a very small percentage of latently infected cells; 
however. For the most part, latently infected cells actually contain defective proviruses, which are of less concern for the cure 
agenda. Image from Murray et al, 2016. 
 
case reports) is that ES seem to have smaller inducible reservoirs and maintain control without 
therapy. In this scenario however, it is unclear if this is cause or consequence: is a smaller reservoir 
really the cause of sustained elite suppression? Or is an overall strong immune response against 
infection the cause of a smaller reservoir and simultaneously elite control?  
To better understand this from the perspective of the second impetus, it is imperative that 
we first appreciate the true size of the reservoir in model ES subjects. While there are currently no 




accurately quantify it. Recently identified, the intact proviral DNA assay (IPDA) uses unique 
primers and HIV proviral DNA from patient cells in a digital droplet PCR assay that distinguishes, 
intact proviruses from defective ones (Bruner et al, 2019). Using this assay, we quantified and 
confirmed the size and frequency of intact proviruses in ES in order to contribute to the growing 
data towards a functional cure. The associated findings are discussed in chapter one of this thesis.  
 
1.3 THE SHOCK-AND-KILL AGENDA 
As previously discussed, the majority of the inducible latent reservoir resides in resting 
CD4+ T cells (Siliciano and Greene, 2011). This quiescent state renders reservoir cells inaccessible 
to immune mediated elimination. One way to get around this challenge, therefore, is to reverse the 
latent state of reservoir cells. This would, theoretically, permit viral replication with subsequent 
inhibition of new rounds of infection by ART while reactivated cells are eliminated by the immune 
system. 
The shock-and-kill agenda is geared towards attempting to achieve this feat. The most 
clinically explored cure strategy to date, it focuses on first reversing latency using small 
pharmacological molecules termed latency reversing agents (LRAs). This is termed a ‘shock’ and 
must be achieved without global T- cell activation (Prins et al, 1999). As shown in Figure 3, the 
activation of these cells should yield two results. First, the production of viral particles which are 
precluded from infecting new cells by ART and second, the production of viral proteins which 
mediate elimination of the host cell by both viral cytopathic effects and/immune effector cell 
cytotoxicity (Deeks, 2012). Thus far, several classes of LRAs, including histone deacetylase 
inhibitors, bromodomain inhibitors and PKC agonists, have been identified (Spivak and Planelles, 




capable of reversing latency, specific LRA combinations tend to yield higher levels of latency 
reversal than single drugs alone (Laird et al, 2015).  
 
 
Figure 3. Proposed flow of events with shock-and-kill. Infected target cells contain intact provirus, which can be induced to 
produce viral proteins via a shock with an LRA. The production of viral proteins mediates the kill by immune sentinel cells while 
ART simultaneously blocks de novo infections. Adapted from Deeks et al, 2012. 
 
Despite its conceptual appeal, there are at least three main challenges associated with the 
pursuit of shock-and-kill as an HIV cure strategy. First is the fact that there are many anatomical 
sites for the latent reservoir (Wong and Yukl, 2017), and when a site is privileged, like the brain, 
it may only permit, to varied degrees, the penetration of a therapeutic agent (Letendre et al, 2008) 
like an LRA or effector cells like sentinel CD8+ T cells. Second is that no properly controlled 
clinical trial with an LRA has, to date, demonstrated success in the main goal of shock-and-kill, 
mediating reductions in the size of the latent reservoir (measured as changes in total cell associated 
DNA; Pace and Frater, 2018). Since blips of viremia suggest that a ‘shock’ is usually achieved, it 
is possible that the reactivated reservoir cells may either be resistant to killing (Huang et al, 2018), 
or fail to be eliminated after ‘kill’, thus warranting the need for enhancement of the immune system 
for control (Montaner and Riley, 2017) or are killed but belong to a much larger than previously 
estimated pool of inducible reservoir cells (Ho et al, 2013). Irrespective of the prevailing challenge, 
CD8 cells, NK cells 
 






more work is required in the ‘kill’ aspect of the agenda. Finally, and perhaps related to point two, 
is that most LRAs are actually drugs employed in the field of oncology with in vitro data 
suggesting that they could have some adverse effects on effector cells needed to mediate effective 
killing after latency has been reversed (Clutton and Jones, 2018, Walker-Sperling et al, 2016, 
Garrido et al, 2016). Although some data suggest this may not be the case- Pace and Frater, 2018, 
Sogaard et al, 2015, if this is true in vivo, it might present one explanation for why in vivo attempts 
at shock-and-kill have failed to reduce the size of the reservoir in candidate patients. In chapter 
two of this thesis, we will discuss our exploration of this third challenge with studies assessing the 
effect of some LRAs individually and in combinations on the activity of ES CD8+ T cell mediated 
immune suppression of HIV.  
 
1.4 ENHANCING IMMUNE CELL FUNCTION FOR THE CONTROL OF HIV: 
FOCUS ON NK CELLS 
Thus far, we have established that HIV/AIDS cannot be cured without the elimination of 
the latent reservoir. We also appreciate that if reservoir eliminating strategies like shock-and-kill 
are to work, they will depend on efficiently functioning immune responses capable of eliminating 
target reservoir cells after reactivation. Unfortunately, in most HIV infected individuals, such 
robust immune responses are absent, thus the need for ART. On one hand, this is caused by poorly 
targeted/functional HIV specific CD8+ T cell responses (Eller et al, 2016, Betts et al, 2006), a 
challenge more evident in non-controllers than in controllers (Pereyra et al, 2014). However, 
immune activation and subsequent exhaustion might also play an important role (Sokoya et al, 




As a chronic infection, the presence of sustained, uncontrolled viral replication leads to 
sustained levels of inflammatory cytokines, particularly interferon stimulated genes mediated by 
type-I interferons. These in turn result in dysregulated immune activation and subsequent immune 
exhaustion that renders effector cells less functional at controlling viral replication (Zhen et al, 
2016, Cheng et al, 2016). Accordingly, immune activation has been determined to be the more 
accurate measure of disease progression than CD4+ T cell decline (Utay and Hunt, 2016). Since 
ART effectively inhibits viral replication, its initiation is associated with concomitant in vivo 
reductions in inflammatory cytokines and, by extension, immune activation, but never to the levels 
of uninfected individuals (Utay and Hunt, 2016). Indeed, unsuccessful shock-and-kill as well as 
vaccine trials suggest that at least one contributing factor to these failing strategies might be 
persistently dysfunctional immune effector cells despite continuous ART. Accordingly, efforts 
exist to strengthen immune responses for improved functional cure efforts, with a focus on CD8+ 
T cells (Perreau et al, 2017, Riley and Montaner, 2017). Of course, this focus is not unwarranted, 
since CD8+ T cells play an important role in the control of HIV replication. However, given their 
evident limitations, including mutations in viruses that lead to escape from targeted epitopes as 
well as down-regulation of MHC-I by viral nef proteins permitting CD8+ T cell immune evasion 
(Garcia et al, 2016, Wonderlich et al, 2011, Jones et al, 2004), it is imperative that the focus on 
immune effector potentiation amidst cure efforts be focused not only on CD8+ T cells, but also on 
other cells capable of complementing CD8+ T cell responses in HIV replication control. An aim 
of this thesis work, and the focus of chapter three, is the bid to achieve this goal with a focus on 
Natural Killer (NK) cells, whose potential value for control of HIV infections is well documented 




NK cells from various individuals with the protein IFN-alpha enhances multiple immune 
functions, while preserving, or strengthening the existing CD8+ T cell responses of study subjects. 
 
 
Figure 4. Varied roles of NK cells in HIV control. Different avenues by which NK cells can help mediate HIV control, including 







2 CHAPTER 1 
ELITE SUPPRESSORS HAVE LOW FREQUENCIES OF INTACT HIV-1 
PROVIRAL DNA 
2.1 ABSTRACT  
Elite controllers or suppressors control viral replication without antiretroviral therapy. We 
used the intact proviral DNA assay to approximate the size of the inducible latent reservoir in elite 
suppressors and found that while the median frequency of both total and intact proviral DNA was 
markedly lower than the frequencies seen in chronic progressors on antiretroviral therapy, there 
was no significant difference in the ratio of intact to total proviral DNA between elite suppressors 
and chronic progressors. 
 
2.2 INTRODUCTION 
A cure for HIV can be achieved through complete eradication of the virus or by a functional 
cure where viral replication is controlled in the absence of antiretroviral therapy (ART) (Siliciano 
and Siliciano, 2016). Elite suppressors who maintain viral loads below the limit of detection of 
clinical assays are a model of a functional cure. While some studies suggest that infection with 
attenuated virus can lead to elite control and/or long-term nonprogression (Zaunders et al, 2011), 
we and others have shown that a subset of elite suppressors are infected with fully replication-
competent virus (Blankson et al, 2007, Lamine et al, 2007, Bailey et al, 2008, Julg et al, 2010, 
Buckheit et al, 2012, Salgado et al, 2014). However, these individuals clearly have smaller 




viral outgrowth assay (QVOA). Furthermore, the QVOA has been shown to underestimate the size 
of the reservoir in chronic progressors (Ho et al, 2013, Bruner et al, 2016), but it is not known 
whether the same finding holds true in elite suppressors. A study based on more than 400 near full-
length sequences of provirus from 28 chronic progressors on ART demonstrated that only 2.4% of 
proviruses in chronic progressors did not contain large deletions or hypermutations (Bruner et al, 
2016). The intact proviral DNA assay (IPDA) is a recently developed digital droplet PCR assay 
that uses primers developed from near full-length proviral sequences to distinguish intact proviral 
DNA from most deleted and/or hypermutated proviral DNA (Bruner et al, 2019). In this study, we 
used the IPDA to approximate the frequency of cells with total and intact proviral DNA in a cohort 
of nine elite suppressors and 10 chronic progressors. 
 
2.3 METHODS 
2.3.1 Quantifying patient total and intact HIV proviral DNA 
 
CD4+ T cells from 10 CP and 9 ES were flash frozen and sent to Accelevir Diagnostics for 
processing. On average, a total of 1.05e6 cells (median of 9.78e5) were delivered for processing 
via IPDA assay. Using a proprietary, company specific established protocol, the total DNA present 
in cells was quantified and from this the frequency of both total HIV DNA, as well as intact HIV 
DNA was quantified using unique primers in a digital droplet PCR that distinguishes intact 
proviruses from defective ones (Bruner et al, 2019). Specifically, the IPDA rests on a premise 
determined from near full-length HIV genome sequencing. Data from these show that together, 
amplicons from the packaging signal and rev response element (RRE) regions of the viral genome 
can identify more than 90% of defective viruses. As such the primers of this assay (optimized for 




packaging signal and RRE are considered conserved regions with high chances of either small 
deletions or hypermutations, respectively. Consequently, the complete amplification of both 
(detected in specific channels by fluorescent probes) suggests the genome interrogated was intact, 
and the failure of one or the other or both to correctly amplify suggests some defect in the 
interrogated viral genome (Bruner et al, 2019). For our study, repeat samples with higher cell 
numbers were delivered where possible for re-testing in the event where no intact proviruses were 
obtained from a patient. When these repeat attempts yielded similar results, we used the Siliciano 
IUPMStats calculator to estimate what the highest possible frequency of intact proviral DNA might 
have been (Rosenbloom et al, 2015). When the intact HIV DNA was imputed in this manner, the 
imputed data was not employed in calculating the ratio of intact to total proviruses.  
2.3.2 Statistics 
 
All graphs and associated statistics were performed in Microsoft Excel and GraphPad 
Prism version 7. 
 
2.4 RESULTS 
2.4.1 Chronic progressors have significantly higher frequency of total and intact HIV DNA 
relative to elite suppressors 
 
All chronic progressors studied in this project had CD4+ T cell counts of greater than 500 
cells/ul (median of 758) and had undetectable viral loads on ART for at least 1 year (median of 5.5 
years). The frequency of total proviral DNA was significantly higher in the chronic progressors 
(median of 602.52 copies per million CD4+ T cells) than the elite suppressors (median of 30.4 
copies per million CD4+ T cells, P = 0.0005, Figure 5a). As shown in Figure 5b, the frequency of 




per million CD4+ T cells) compared with elite suppressors (median of 1.61 copies per million 
CD4+ T cells, P = 0.0159). 
2.4.2 There is no significant difference in the proportion of intact to total HIV DNA between 
elite suppressors and chronic progressors  
 
After determining the individual frequencies of total and intact HIV DNA in both groups 
of patients, we next asked whether the proportion of total proviral DNA that was intact was 
different between the same two patient groups (Figure 5c). Interestingly, we found that, there was 
no significant difference in the ratio of intact to total proviral DNA in chronic progressors versus 
elite suppressors. While this was amongst independent patients, we also wanted to determine if 
this observation was true amongst transmission couples specifically discordant ones. We have 
previously described the transmission of virus from chronic progressor 10 to elite suppressor 9 
(Bailey et al, 2008). The transmission occurred 20 years ago and elite suppressor 9 has maintained 
elite control since then while chronic progressor 10 has been on ART. The frequency of total 
proviral (Figure 5d) and intact proviral DNA (Figure 5e) was much higher in chronic progressor 
10 than in elite suppressor 9, but the ratio of intact to total proviral DNA was similar in the two 






Figure 5. Total and intact provirus quantification. Frequency of total (a) and intact (b) proviruses were quantified, in 10 chronic 
progressors (red circles) and nine elite suppressors (blue squares) using the intact proviral DNA assay. The open symbol denotes a 
value that was below the limit of detection of the assay and represents the highest possible frequency of intact proviral DNA. The 
ratio of intact to total DNA is shown for chronic progressors and elite suppressors in (c). Bars represent the median values with 
95% confidence intervals. The frequency of total (d) and intact (e) proviruses were quantified in the chronic progressor 10/elite 
suppressor 9 transmission pair. The ratio of intact to total DNA is shown in (f). The nonparametric, Kruskal–Wallis test was 













Table 1: Clinical characteristics and reservoir measurements in ES in our study 












DNA per million 
CD4+ T cells 
Intact 
proviral 
DNA per million 




ES3 F 26 NA 1014 HLA-B*57 6.78 < 1.00 <0.04 18 
ES5 F 27 NA 918 HLA-B*57 108.1 1.61 <0.03 25 
ES6 F 25 NA 916 HLA-B*57 30.41 1.25 < 0.02 29 
ES9 F 21 NA 680 HLA-B*27 
HLA-B*57 
44.34 1.04 ND ND 
ES18 F 7 NA 970 None 19.00 5.58 ND ND 
ES24 M 8 NA 1269 HLA-B*57 372.57 191.31 4.57 5 
ES31 F 11 NA 956 HLA-B*27 
HLA-B*57 
63.14 5.33 ND ND 
ES46 M 13 NA 667 HLA-B*57 9.85 1.95 <0.06 12 
ES51 M 13 NA 1015 HLA-B*57 1.45 0.82 <0.03 20 
NA: Not applicable 
ND: Not done 
 
2.5 DISCUSSION 
We compared the levels of intact proviral DNA to the frequency of cells with replication-
competent virus as measured by the QVOA from a separate but recent study from our group. Elite 
suppressor 24, who has the highest level of intact proviral DNA in our cohort (191 copies per 
million CD4+ T cells), also has a high frequency of cells positive for replication competent virus 
[4.57 infectious units per million (IUPM)] (Veenhuis et al, 2018). In contrast, five elite suppressors 
who had less than two copies of intact proviral DNA per million CD4+ T cells had IUPM values 
of less than 0.06 (Table 1), implying that low frequencies of intact proviral DNA were associated 




Prior studies have shown that elite suppressors have lower frequencies of total and 
integrated DNA (Lambotte et al, 2005, Hatano et al, 2009, Graf et al, 2011, Mendoza et al, 2012, 
Hatano et al, 2013, Canoui et al, 2017, Garcia et al, 2017, Avettand-Fenoel et al, 2019), lower 
levels of baseline and inducible cell associated RNA (Noel et al, 2016, Pohlmyer et al, 2017), and 
lower frequencies of cells positive for replication-competent virus (Blankson et al, 2007, Julg et 
al, 2010, Salgado et al, 2014, Mendoza et al, 2012, Noel et al, 2016, Chun et al, 2013). These 
different assays measure different aspects of the viral reservoir, and while there have been studies 
comparing these assays in chronic progressors (Bruner et al, 2019, Eriksson et al, 2013), this is the 
first time measurements of intact proviral DNA have been compared with measurements of the 
inducible replication-competent viral reservoir in elite suppressors. This is important as elite 
suppressors may represent a model of a functional cure and their small reservoir size may 
approximate what can be achieved with different curative interventions. We show here that while 
elite suppressors have much lower total and intact DNA levels than chronic progressors, the ratio 
of intact to total DNA is similar to the ratios present in chronic progressors. This would imply that 
elite suppressors do not have a higher proportion of defective viral DNA than chronic progressors. 
It remains unclear whether the small reservoir size is a cause or consequence of elite control, but 
lower peak viral loads and earlier control of viral replication has been reported in some elite 
suppressors (Goujard et al, 2009). It is possible that this early control of viral replication limits the 
seeding of the reservoir as has been described in individuals who are treated with ART during 
primary infection (Robb and Ananworanich, 2016). However, elite suppressor 24, had levels of 
intact DNA that were higher than the levels seen in our chronic progressors. This would suggest 





Our results have implications for HIV cure strategies as they further elucidate the viral 





3 CHAPTER 2 
THE EFFECT OF INGENOL-B ON THE SUPPRESSIVE CAPACITY OF ELITE 
SUPPERSSOR HIV-SPECIFIC CD8+ T CELLS 
3.1 ABSTRACT 
Some latency-reversing agents (LRAs) inhibit HIV-specific CD8+ T cell responses. In a 
prior study of protein kinase C (PKC) agonists, we found that bryostatin-1 inhibited elite 
controller/suppressor (ES) CD8+ T cell suppressive activity whereas prostratin had no effect. 
Ingenol-B is another PKC agonist with potent LRA activity both by itself and in combination with 
the bromodomain inhibitor JQ1; however, its effect on CD8+ T cell mediated control of HIV-1 
replication is unknown. Accordingly, CD8+ T cells were isolated from ES and treated with 
bryostatin-1, prostratin, ingenol-B, and JQ1 as well as a combination of each PKC-agonist with 
JQ1. The cells were then tested in the viral suppression assay. Furthermore, to assess possible 
mechanisms of inhibition, CD8+ T cells were treated with the LRAs and analyzed for the 
expression of various immune cell markers. Our findings show that Ingenol-B had no effect on the 
ability of ES CD8+ T cells to suppress viral replication, however, the combination of ingenol-B 
and JQ1 caused a modest, but significant decrease in this suppressive capacity. The mechanism of 
the inhibitory effect of the JQ1 and ingenol-B combination relative to ingenol-B alone was unclear 
but the effect appeared to be dose dependent. In summary, ingenol-B does not inhibit HIV-specific 
CD8+ T cell responses in vitro. These responses are however modestly inhibited when 100nM 
ingenol-B is combined with JQ1. Since HIV-specific CD8+ T cell activity may be essential for the 








Shock-and-kill strategies have been proposed as a possible mechanism for HIV-1 
eradication (Siliciano and Siliciano, 2013, Archin and Margolis, 2014). The strategies involve the 
use of latency-reversing agents (LRAs) such as Histone Deacetylase (HDAC) inhibitors and PKC-
agonists to “shock” latently infected CD4+ T cells and myeloid cells into producing viral proteins 
that could then be recognized by effector cells leading to the “kill” component of the strategy. 
Several studies have shown that LRAs do in fact lead to an increase in HIV transcription and/or 
blips of viremia in clinical trials; however, this has not been accompanied by a decrease in the size 
of the latent reservoir (Archin et al, 2012, Elliot et al, 2014, Rasmussen et al, 2014, Sogaard et al, 
2015). One possible reason for this disconnect is that the number of latently infected cells that 
were eradicated in these studies represent a very small proportion of the total latent reservoir. 
Another potential explanation is that the LRAs inhibit the responses of HIV-specific effector cells 
thereby leading to ‘shocking’ without ‘killing’.  
Recent studies have indeed shown that different classes of LRAs inhibit the responses of 
natural killer (NK) cells (Pace et al, 2016, Garrido et al, 2016), T cells (Akimova et al, 2012), and 
HIV-specific CD8+ T cells (Jones et al, 2014, Walker-Sperling et al, 2016, Clutton et al, 2016) 
and others may affect the susceptibility of CD4+ T cells to HIV-1 infection (Lucera et al, 2014). 
We previously showed that the PKC-agonist bryostatin-1 inhibited the suppressive capacity of 
primary CD8+ T cells from elite controllers/suppressors (ES) whereas the PKC-agonist prostratin 




were shown to have synergistic effects on latency reversal (Laird et al, 2015) also had different 
effects on HIV-specific CD8+ T cells (Walker-Sperling et al, 2016). For instance, the combination 
of bryostatin-1 with the HDAC inhibitor romidepsin induced more inhibition of the suppressive 
capacity of T cells than either drug alone, whereas the combination of prostratin with the 
bromodomain inhibitor JQ1 did not significantly impact the said HIV-specific response (Walker-
Sperling et al, 2016).  
Ingenol-B is a relatively new addition to the gradually increasing list of potential candidates 
for latency reversal (Darcis et al, 2015, Shang et al, 2015). It is derived via a series of chemical 
reactions that result in a selective esterification at the carbon 3 position of ingenol obtained from 
ingenol esters of the Euphorbiacea tirucalli plant (Pandelo Jose et al, 2014). While ingenol itself 
is thought to be less efficient at enhancing viral replication (Fujiwara et al, 1998), its derivatives, 
such as ingenol-B and ingenol dibenzoate, are known to demonstrate potent latency reversal when 
used both alone (Abreu et al, 2014, Spivak et al, 2015) and in combination with JQ1 in vitro (Darcis 
et al, 2015, Jiang et al, 2015), and also when used with the HDAC inhibitor vorinostat in vivo in a 
recent SIV study (Gama et al, 2017). This synergy of viral reactivation exhibited when ingenol 
derivatives are combined with other LRAs likely stems from the different, but complimenting, 
mechanisms through which each drug reactivates viral LTR- with ingenol achieving this via the 
PKC-NFκB pathway, and JQ1 and vorinostat doing so via p-TEFb recruitment, and HDAC 
inhibition, respectively.  
Given their efficacy at latency reversal both alone and in combination with other drugs 
such as JQ1, ingenol derivatives appear to be promising candidates for the shock-and-kill cure 
agenda. However, while much has been done to assess its potency as an LRA, no studies have 




replication. This question is addressed in this study with a focus on the effect of the ingenol 
derivative ingenol-B on CD8+ T cells when used either alone or in combination with the 
bromodomain inhibitor JQ1. We also assessed the effects of other PKC agonists, and their 
combinations, on CD8+ T cell function, using CD8+ T cells form ES, since the cells of these 
patients have been shown to have superior, HIV-specific suppressive capacities (O’Connell et al, 
2009, Migueles et al, 2002, Betts et al, 2006, Saez-Cirion et al, 2007, Migueles et al, 2008, 




3.3.1 Patients  
 
HIV-1 positive and HIV-1 negative blood samples were obtained from donors with written, 
informed consent and handled according to a Johns Hopkins University IRB approved protocol. 
Elite suppressors are patients who have maintained undetectable viral loads without antiretroviral 
therapy. Chronic progressors (CPs) are patients on antiretroviral therapy who have maintained 
undetectable viral loads for more than 1 year. Healthy donors (HDs) are HIV negative donors. The 












Table 2: Clinical characteristics of patients 
 
 
3.3.2 The effect of LRAs on elite suppressor CD8+ T cell suppressive capacity  
 
Peripheral blood mononuclear cells (PBMCs) were obtained from whole blood via Ficoll 
Paque PLUS gradient centrifugation (GE Healthcare Life Sciences). CD8 + T cells were isolated 
from PBMCs of elite suppressors by positive selection with Miltenyi beads. CD4+ T cells were 
isolated from the CD8+ T cell negative cells by negative selection using Miltenyi beads. CD8 + T 
cells from elite suppressor patients were treated for six hours with either media, DMSO (negative 
control, 0.1%), JQ1 (1μM; Sigma Aldrich), ingenol-B (100nM; Amazoˆnia Fitomedicamentos 
Ltda.), bryostatin-1 at two concentrations (10nM, 1nM), prostratin (0.3μM; Sigma Aldrich), or 
PMA (positive control, 50ng/mL; Sigma). In some experiments, the PKC-agonists were combined 
with JQ1 at the same concentrations. All drug concentrations were selected based on either 
physiological relevance in clinical studies (bryostatin at 1nM) or previous work that demonstrated 
them to be optimal for latency reversal (Laird et al, 2015, Smith et al, 2011). Bulk CD4 + T cells 
were spinoculated at 1200 × g for two hours at 37˚C with HIV-1 NL4 − 3 Δ Env − GFP at 
200ng/100,000 cells. HIV-1 NL4 − 3 Δ Env − GFP is a replication incompetent lab strain 
pseudotype virus with env replaced with gfp and whose expression is controlled by the HIV 




added at a 1:1 effector:target ratio to the spinoculated CD4 + T cells. The cells were co-cultured 
for three days prior to Flow cytometry (FACS) analysis (Figure 6). 
3.3.3 Effects of latency reversing agents on cell death, proliferation, exhaustion, and 
activation immune markers  
 
PBMCs were isolated from HDs or CPs, seeded at 1x106 cells /well in a 48 well plate and 
treated for 6 hours at 37˚C with the individual LRAs or LRA combinations listed above. Cells 
were washed three times after drug treatment and re-seeded into 96 well plates at 200,000 
cells/well/treatment type and assessed for immune marker expression via FACS at four time 




Figure 6. A representative flow diagram of the suppression assay 
 
We also explored the potential of select LRAs/LRA combinations, to either induce proliferation, 




and CD8+ T cells were isolated from donor PBMCs and combined at a 1:1 ratio. They were washed 
with pre-warmed PBS and exposed to 1uM CFSE (diluted in DMSO to 5uM, then warm PBS to 
1uM) at a 1x106 cells/ml of CFSE with gentle vortexing. Cells were then incubated for 10 minutes 
at 37˚C and CFSE quenched with 5 times original volume of cold media followed by a 5 minute 
incubation at 4˚C. Cells were washed one more time with media and treated for 6 hours with select 
LRAs or LRA combinations in 96 well plates at 200,000 cells/well/treatment. Drug combinations 
are the same as used a prior, except for the addition of ingenol-B at 10nM and PMA/Ionomycin at 
50ng/ml and 1uM respectively. At the end of this incubation, cells were extensively washed, and 
cultured for an additional 3 days, after which cell death and proliferation were assessed by FACS. 
For Ki-67 staining, cells were treated with drugs for 6 hours prior to cell culture. On day 3, 
antibodies to surface markers were added and the cells were then fixed with 70% cold ethanol 
followed by intracellular staining with the Ki-67 antibody (Biolegend). 
3.3.4 FACS analysis  
 
For the suppression assay, the following antibodies were used: CD3 (Pacific Blue, clone 
UCHT1, BioLegend), CD8 (PE, clone RPA-T8, BD Pharmingen) and CD69 (APC, clone FN50, 




The following markers were used to assess cell death, immune activation, and exhaustion: CD3 
(PE, clone UCHT1, BD Pharmingen), CD8 (APC-H7, clone SK1, BD Biosciences), CD69 (APC, 




V450, BD Biosciences), PD1 (PerCP/Cy5.5, clone EH12.2H7, BioLegend) CD25 (FITC, clone 
M-A251, BD Pharmingen), HLA-DR (PE, clone L243, Biolegend) and Ki-67 (APC, clone Ki67, 
Biolegend). Proliferation was assessed using the CellTrace cell proliferation kit from Invitrogen 
and read in the FITC channel. 
3.3.5 Statistics  
 
All statistical analysis and associated graphs were generated in GraphPad Prism 7. For each 
parameter studied, statistical significance was assessed using a one-way ANOVA with repeated 
measures. The Geisser-Greenhouse Correction was also employed to account for violations of 
sphericity. In experiments that entailed replicates, standard deviations were used to determine 
variances from corresponding means. In all cases, the Dunnett’s Multiple Comparison’s test was 
used to assess variations of treatment groups from the DMSO control. Multiplicity adjusted P 
values were reported to assess significance with the following p-value demarcations: ns (p>0.05), 
* (p<0.05), ** (p<0.01), *** (p<0.001), **** (p<0.0001).  
 
3.4 RESULTS 
3.4.1 Ingenol-B does not inhibit ES CD8+ T cell suppressive capacity  
 
 To determine the effect of individual drugs on the suppressive capacity of HIV-specific 
CD8+ T cells, we treated CD8+ T cells isolated from elite suppressors for 6 hours with three 
different doses of ingenol-B that have been tested in vitro, and then co-cultured them (after 
extensive washes) over a 3-day period with autologous CD4+ T cells spinoculated with a lab strain 
HIV pseudotype virus. There was no inhibition of CD8+ T cell suppressive capacity with 10nM, 




the 100nM dose for comparison to other LRAs including the bromodomain inhibitor JQ1 and the 




Figure 7. Elite suppressor CD8 + T cell responses are not inhibited by ingenol-B. CD8 + T cells from 5 ES were either not 
treated (NT) or pre-incubated with DMSO or ingenol-B at 3 different doses for 6 hours, washed, then added to autologous CD4 + 
T cells infected with a lab strain HIV-1 pseudotype virus at a 1:1 effector:target ratio. Percent suppression of viral replication was 
determined after 3 days. Triplicates were performed and mean values are shown for each individual. 
 
The combination of ingenol-B and JQ1 has a modest inhibitory effect on ES CD8+ T cell 
suppressive capacity 
 As previously described (Walker-Sperling et al, 2016), bryostatin-1 caused significant 
inhibition of the suppressive capacity of ES CD8+ T cells at 10nM (19.22% suppression versus 
59.33% for DMSO treated cells, p = 0.002) whereas prostratin and JQ1 individually had no effect 
(59.74% suppression and 63.77% suppression respectively, Figure 8). CD8+ T cells treated with 





with the DMSO vehicle (65.33% suppression, p = 0.567, Figure 8). While neither100nM of 
ingenol-B nor JQ1 had a significant effect on ES CD8+ T cells, the combination of the 2 drugs had 
a modest, but significant, inhibitory effect on the suppressive capacity of the T cells (39.99% 
suppression compared to 59.33% suppression with DMSO, p = 0.033). A more pronounced 
inhibitory effect was seen with the combination of bryostatin-1 (10nM) and JQ1 (18.23% 
suppression), and no significant inhibition was seen with the prostratin/JQ1 combination (45.23% 
suppression) as previously described (Walker-Sperling et al, 2016). 
 
 
Figure 8. Elite suppressor CD8 + T cell responses are modestly inhibited by the combination of ingenol-B and JQ1. CD8 + 
T cells from 6 ES were pre-incubated with indicated LRAs for 6 hours, washed, then added to autologous CD4 + T cells infected 
with a lab strain HIV-1 pseudotype virus at a 1:1 effector:target ratio. Percent suppression of viral replication was determined after 
3 days. Triplicates were performed and mean values are shown for each individual. One-way repeated measures ANOVAs were 
used to determine significance for each of the two sets of experiments. Symbols directly above treatments indicate differences from 
the DMSO control (* p< 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). Cells were either non treated (NT) or treated with 
DMSO (0.1%), bryostatin-1 at 10 or 1nM (BRYO 10 and BRYO 1 respectively), prostratin at 0.3uM (PRO), ingenol-B at 100nM 
(ING), PMA at 50ng/mL (PMA) and JQ1 at 1uM (JQ1). In some experiments, the PKC-agonists were combined with JQ1 at the 





3.4.2 Ingenol-B induces high levels of CD8+ T cell activation, modest cell death and PD1 
expression and no cell proliferation 
 
 In order to address the different effects of the inhibitory (bryostatin-1) and non-inhibitory 
(prostratin and ingenol-B) PKC-agonists, we measured the amount of immune activation they 
induced on CD8+ T cells from healthy donors (Figure 9). With the exception of JQ1, which slightly 
increased levels of CD69, all drugs induced high levels of CD69 expression after 6 hours of drug 
exposure. This activation was sustained for bryostatin-1 and ingenol-B, but by the 24 hour time 
point, CD69 expression on CD8+ T cells exposed to prostratin had begun to decline and by 2 days 
there was no difference in the level of expression between prostratin and DMSO treated cells. 
Similarly, besides prostratin and bryostatin at 1nM, cells treated with the combination of JQ1 and 
PKC agonists had sustained levels of activation as cells treated with the PKC-agonists alone. A 
similar pattern was seen with cells obtained from chronic progressors on ART (Figure 10). We 
also examined other activation markers and found that aside from PMA, and PMA/Iono, none of 
the LRAs induced significant expression of CD25 (Figure 11) or co-expression of HLA-DR and 
CD38 (Figure 12).  
 Ingenol-B treatment resulted in a modest but significant increase in annexin V expression 
at 2 days, but no significant increase in cell death was observed at any other time point (Figure 13 
and Figure 14). The percentages of CD8+ T cells expressing PD1 after ingenol-B and ingenol-
B/JQ1exposures were also slightly elevated at the 1 and 2 day time points but not enough to explain 
the differences in suppressive capacity of ES CD8+ T cells (Figure 15 and Figure 16). We also co-
cultured purified CD4+ and CD8+ T cells to more closely approximate the experiment we 
performed with the ES CD8+ T cells and observed no significant increase in CD8+ T cell death 
on day 3 in this system, following a 6 hour exposure to ingenol-B or ingenol-B and JQ1 (Figure 




difference in responses to ingenol-B versus ingenol-B and JQ1. We found that the LRAs did not 
induce any non-specific proliferation of CD8+ T cells as determined by CFSE dilution or Ki-67 
expression (Figure 18). 
 
Figure 9. CD69 expression is upregulated on HD CD8+ T cells following treatment with PKC-agonists. PBMCs from 8 HDs 
were treated with LRAs for 6 hours, washed, then cultured for up to 3 days and examined for CD69 expression on CD8 + T cells. 
Mean expression ± standard error is indicated for each treatment at (A) 6 hours, (B) day 1, (C) day 2 and (D) day 3. Symbols 
directly above treatments indicate differences from the DMSO control (* p< 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). 
Cells were either non treated (NT) or treated with DMSO (0.1%), bryostatin-1 at 10 or 1nM (BRYO 10 and BRYO 1 respectively), 
prostratin at 0.3uM (PRO), ingenol-B at 100nM (ING), PMA at 50ng/mL (PMA) and JQ1 at 1uM (JQ1). In some experiments the 





Figure 10. CD69 expression is upregulated on CP CD8+ T cells following treatment with PKC-agonists. PBMCs from 6 CPs 
were treated with LRAs for 6 hours, washed, then cultured for up to 3 days and examined for CD69 expression on CD8 + T cells. 
Mean expression ± standard error is indicated for each treatment at (A) 6 hours, (B) day 1 and (C) day 3. Symbols directly above 
treatments indicate differences from the DMSO control (* p< 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). Cells were either 
non treated (NT) or treated with DMSO (0.1%), bryostatin-1 at 10nM (BRYO), ingenol-B at 1000, 100 or 10nM (ING 1000, ING 
100, ING 10 respectively), PMA at 50ng/mL (PMA) and JQ1 at 1uM (JQ1). In some experiments the PKC-agonists were combined 
with JQ1 at the same concentrations (BRYO 10/JQ1, ING 100/JQ1). PMA and ionomycin (PMA/IONO, 50ng/ml and 1uM 






Figure 11. CD25 expression is not upregulated on CP CD8+ T cells following treatment with LRAs. PBMCs from 6 CPs were 
treated with LRAs for 6 hours, washed, then cultured for up to 3 days and examined for CD25 expression on CD8 + T cells. Mean 
expression ± standard error is indicated for each treatment at (A) 6 hours, (B) day 1 and (C) day 3. Symbols directly above 
treatments indicate differences from the DMSO control (* p< 0.05). Cells were either non treated (NT) or treated with DMSO 
(0.1%), bryostatin-1 at 10nM (BRYO), ingenol-B at 1000, 100 or 10nM (ING 1000, ING 100, ING 10 respectively), PMA at 
50ng/mL (PMA) and JQ1 at 1uM (JQ1). In some experiments the PKC-agonists were combined with JQ1 at the same concentrations 






Figure 12. CD38 and HLA-DR co-expression is not upregulated on CP CD8+ T cells following treatment with LRAs. PBMCs 
from 6 CPs were treated with LRAs for 6 hours, washed, then cultured for up to 3 days and examined for CD38 and HLA-DR co-
expression on CD8 + T cells. Mean expression ± standard error is indicated for each treatment at (A) 6 hours, (B) day 1 and (C) 
day 3. Symbols directly above treatments indicate differences from the DMSO control (* p< 0.05). Cells were either non treated 
(NT) or treated with DMSO (0.1%), bryostatin-1 at 10nM (BRYO), ingenol-B at 1000, 100 or 10nM (ING 1000, ING 100, ING 
10 respectively), PMA at 50ng/mL (PMA) and JQ1 at 1uM (JQ1). In some experiments the PKC-agonists were combined with JQ1 
at the same concentrations (BRYO 10/JQ1, ING 100/JQ1). PMA and ionomycin (PMA/IONO, 50ng/ml and 1uM respectively) 








Figure 13. Ingenol-B and ingenol-B/JQ1 combination causes modest levels of cell death in HD CD8+ T cells. PBMCs from 8 
HDs were isolated and treated with LRAs for 6 hours, washed, then cultured for up to 3 days and examined for cell death as 
measured by percent annexin V expression. Mean expression ± standard error is indicated for each treatment at (A) 6 hours, (B) 
day 1, (C) day 2 and (D) day 3. Symbols directly above treatments indicate differences from the DMSO control (* p< 0.05, ** p < 
0.01, *** p < 0.001, **** p < 0.0001). Cells were either non treated (NT) or treated with DMSO (0.1%), bryostatin-1 at 10 or 1 
nM (BRYO 10 and BRYO 1 respectively), prostratin at 0.3uM (PRO), ingenol-B at 100nM (ING), PMA at 50ng/mL (PMA) and 
JQ1 at 1uM (JQ1). In some experiments the PKC-agonists were combined with JQ1 at the same concentrations (BRYO 10/JQ1, 





Figure 14. Ingenol-B/JQ1 combination causes modest levels of cell death in CP CD8+ T cells. PBMCs from 6 CPs were 
isolated and treated with LRAs for 6 hours, washed, then cultured for up to 3 days and examined for cell death as measured by 
percent annexin V expression. Mean expression ± standard error is indicated for each treatment at (A) 6 hours, (B) day 1 and (C) 
day 3. Symbols directly above treatments indicate differences from the DMSO control (* p< 0.05, ** p < 0.01). Cells were either 
non treated (NT) or treated with DMSO (0.1%), bryostatin-1 at 10nM (BRYO), ingenol-B at 1000, 100 or 10nM (ING 1000, ING 
100, ING 10 respectively), PMA at 50ng/mL (PMA) and JQ1 at 1uM (JQ1). In some experiments the PKC-agonists were 
combined with JQ1 at the same concentrations (BRYO 10/JQ1, ING 100/JQ1) or with PMA and ionomycin (PMA/IONO, 







Figure 15. Ingenol-B/JQ1 combination causes transient, slightly higher levels of % PD1 expression on HD CD8+ T cells. 
PBMCs from 8 HDs were treated with LRAs for 6 hours before being washed and cultured for up to 3 days and examined for cell 
exhaustion as measured by percent PD1 expression. Mean expression ± standard error is indicated for each treatment at (A) 6 hours, 
(B) day 1, (C) day 2 and (D) day 3. Symbols directly above treatments indicate differences from the DMSO control (* p< 0.05, ** 
p < 0.01, *** p <0.001, **** p < 0.0001). Cells were either non treated (NT) or treated with DMSO (1%), bryostatin-1 at 10 or 1 
nM (BRYO 10 and BRYO 1 respectively), prostratin at 0.3uM (PRO), ingenol-B at 100nM (ING), PMA at 50ng/mL (PMA) and 
JQ1 at 1uM (JQ1). In some experiments the PKC agonists were combined with JQ1 at the same concentrations (BRYO 10/JQ1, 






Figure 16. Ingenol-B/JQ1 combination causes slightly higher levels of % PD1 expression on CP CD8+ T cells. PBMCs from 
6 CPs were isolated and treated with LRAs for 6 hours, washed, then cultured for up to 3 days and examined for cell exhaustion as 
measured by percent PD1 expression. Mean expression ± standard error is indicated for each treatment at (A) 6 hours, (B) day 1, 
and (C) day 3. Symbols directly above treatments indicate differences from the DMSO control (* p< 0.05). Cells were either non 
treated (NT) or treated with DMSO (0.1%), bryostatin-1 at 10nM (BRYO), ingenol-B at 1000, 100 or 10nM (ING 1000, ING 100, 
ING 10 respectively), PMA at 50ng/mL (PMA) and JQ1 at 1uM (JQ1). In some experiments the PKC-agonists were combined 







Figure 17.  LRAs do not increase levels of cell death in HD CD8+ T cells following incubation with CD4+ T cells. PBMCs 
were isolated from 6 HDs and CD4+ and CD8+ T cells enriched. Cells were combined at a 1:1 ratio, co-cultured and treated with 
LRAs for 6 hours after which cells were extensively washed and incubated for an additional 3 days before examining for CD8+ T 
cell death by percent annexin V expression. Mean expression ± standard error is indicated for each treatment at day 3. No significant 
differences in cell death were observed, relative to the DMSO control. Cells were either non treated (NT) or treated with DMSO 
(1%), ingenol-B at 100nM or 10nM (ING 100 or ING 10), PMA at 50ng/mL (PMA), JQ1 at 1uM (JQ1) and ingenol-B/JQ1 






Figure 18. Ingenol-B does not induce proliferation of CD8+ T cells. (A) PBMCs were isolated from 6 HDs and CD4+ and CD8+ 
T cells enriched. Cells were combined at a 1:1 ratio and exposed to CellTrace CFSE. They were treated with LRAs for 6 hours 
incubated for an additional 3 days before examination for CD8+ T cell proliferation by percent CFSE expression. Mean expression 
± standard error is indicated for each treatment at day 3. Cells were either non treated (NT) or treated with DMSO (1%), ingenol-
B at 100nM or 10nM (ING 100 or ING 10), PMA at 50ng/mL (PMA), PMA/Ionomycin (PMA/IONO, 50ng/ml and 1uM 
respectively), JQ1 at 1uM (JQ1) and ingenol-B/JQ1 combinations at the same concentrations (ING 100/JQ1, ING 10/JQ1). (B) 
PBMCs were isolated from 4 CPs and treated for 6 hours with LRAs. They were then extensively washed and incubated for an 
additional 3 days before intracellular staining with the Ki-67 monoclonal antibody. Mean expression ± standard error is indicated 






3.4.3 Ingenol-B and ingenol-B/JQ1 induce transient downregulation of CD3 but have no 
effect on surface CD8 expression 
 
 Prior studies have shown that ingenol-B causes a significant downregulation of surface 
CD4 expression (Abreu et al, 2014, Spivak et al 2015) and thus we asked whether a similar 
downregulation of CD8 might play a role in the inhibitory effect of the ingenol-B/JQ1 
combination. We found that while CD8 surface levels were slightly lower in cells treated with 
bryostatin-1 at the day 2 time point (normalized MFI of 0.914 compared to DMSO treated cells of 
0.996, p = 0.009), cells treated with 100nM ingenol-B and ingenol-B/JQ1 had similar levels of 
CD8 as cells treated with the DMSO vehicle (normalized MFIs of 1.046 and 0.943 respectively, 
Figure 19). In contrast, CD3 was significantly downregulated on CD8+ T cells that were treated 
with bryostatin-1 at 10nM and 1nM (normalized MFIs of 0.574 and 0.787 respectively), ingenol-
B at 100nM (normalized MFI of 0.645), bryostatin/JQ1 (normalized MFI of 0.5113) and ingenol-
B/JQ1(normalized MFI of 0.539) at the 6 hour time point (Figure 20 and Figure 21). Interestingly, 
this downregulation was transient for ingenol-B and ingenol-B/JQ1 treated cells, such that CD3 
had normalized by the 24-hour time point. In contrast, cells treated with bryostatin-1 and 






Figure 19. Surface CD8 expression in HD is modestly downregulated by some LRAs. PBMCs from 8 HDs were treated with 
LRAs for 6 hours before being washed and then cultured for up to 3 days and examined for CD8 expression. Mean expression ± 
standard error is indicated for each treatment at (A) 6 hours, (B) day 1, (C) day 2 and (D) day 3. Symbols directly above treatments 
indicate differences from the DMSO control (* p< 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). Cells were either non treated 
(NT) or treated with DMSO (0.1%), bryostatin-1 at 10 or 1nM (BRYO 10 and BRYO 1 respectively), prostratin at 0.3uM (PRO), 
ingenol-B at 100nM (ING), PMA at 50ng/mL (PMA) and JQ1 at 1uM (JQ1). In some experiments the PKC-agonists were combined 





Figure 20. Surface CD3 expression in HD is downregulated following treatment with PKC-agonists. PBMCs from 8 HDs 
were treated with LRAs for 6 hours before being washed and then cultured for up to 3 days and examined for CD3 expression. 
Mean expression ± standard error is indicated for each treatment at (A) 6 hours, (B) day 1, (C) day 2 and (D) day 3. Symbols 
directly above treatments indicate differences from the DMSO control (* p< 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). 
Cells were either non treated (NT) or treated with DMSO (0.1%), bryostatin-1 at 10 or 1nM (BRYO 10 and BRYO 1 respectively), 
prostratin at 0.3uM (PRO), ingenol-B at 100nM (ING), PMA at 50ng/mL (PMA) and JQ1 at 1uM (JQ1). In some experiments the 






Figure 21. Surface CD3 expression in CP is downregulated following treatment with PKC-agonists. PBMCs from 6 CPs were 
isolated and treated with LRAs for 6 hours, washed, then cultured for up to 3 days and examined for CD3 expression. Mean 
expression ± standard error is indicated for each treatment at (A) 6 hours, (B) day 1, and (C) day 3. Symbols directly above 
treatments indicate differences from the DMSO control (* p< 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). Cells were either 
non treated (NT) or treated with DMSO (0.1%), bryostatin-1 at 10nM (BRYO), ingenol-B at 1000, 100, or 10nM (ING 1000, ING 
100, ING 10 respectively), PMA at 50ng/mL (PMA) and JQ1 at 1uM (JQ1). In some experiments the PKC-agonists were combined 







3.4.4 The combination of a lower dose of Ingenol-B with JQ1 has no significant inhibitory 
effect on ES CD8+ T cell suppressive capacity 
 
 In order to determine whether the modest inhibitory effect of the combination of ingenol-
B with JQ1 was dependent on the dose of ingenol-B, we performed experiments with 10nM of the 
drug in combination with the same dose of JQ1. As shown in Figure 22, no inhibition of the 
suppressive capacity of CD8+ T cells was observed with this specific combination. 
 
 
Figure 22. Elite suppressor CD8 + T cell responses are not inhibited by 10nM ingenol-B in combination with JQ1. CD8 + T 
cells from 5 ES were pre-incubated with 10nM ingenol-B and 1uM JQ1 for 6 hours, washed, then added to autologous CD4 + T 
cells infected with a lab strain HIV-1 pseudotype virus at a 1:1 effector:target ratio. Percent suppression of viral replication was 









 Ingenol derivatives have been shown to function efficiently both as monotherapy and in 
combination with other drugs such as JQ1 and vorinostat in vitro (Darcis et al, 2015, Abreu et al 
2014, Spivak et al, 2015, Jiang et al, 2015) and in vivo (Gama et al 2017). While some ingenol 
derivatives are thought to function via alternative pathways (Fujiwara et al, 1998), it is generally 
established that most ingenol derivatives, including ingenol-B, function as PKC agonists, reversing 
latency via the PKC-NFκB pathway (Abreu et al 2014, Spivak et al, 2015, Jiang et al, 2015). 
Besides PKC activation, ingenol-B has also been shown to facilitate transcript elongation via the 
recruitment of specific P-TEFb components namely CDK9 and CyclinT1 (Pandelo Jose et al, 
2014). Ingenol-B is also thought to be capable of inhibiting viral propagation by downregulating 
HIV receptors and co-receptors (CD4, CCR5 and CXCR4) (Abreu et al 2014, Spivak et al, 2015). 
This drug may therefore be a promising agent to test in clinical trials. 
 A recent study has shown that the reversal of latency by itself is not sufficient to eliminate 
latently infected CD4+ T cells, and that HIV-specific CD8+ T cells may also be needed for the 
eradication of these cells (Shan et al, 2012). This finding has prompted additional studies which 
have now produced significant data to suggest that some LRAs may inhibit NK cell and CD8+ T 
cell activity (Pace et al, 2016, Garrido et al, 2016, Akimova et al, 2012, Jones et al, 2014, Walker-
Sperling et al, 2016, Clutton et al, 2016) and thus may not be the optimal candidates for shock-
and-kill strategies. In a recent study, we showed that agents such as the HDAC inhibitors 
romidepsin and panobinostat, and the PKC agonist bryostatin-1, inhibited the responses of ES 
CD8+ T cells in viral suppression assays (Walker-Sperling et al, 2016). We also tested 




like romidepsin and bryostatin-1, inhibited CD8+ T cell responses to a greater degree than either 
drug alone. 
 In this study, we screened ingenol-B to determine whether it inhibited HIV-specific CD8+ 
T cell responses. We used CD8+ T cells from ES since these patients have potent HIV-specific 
CD8+ T cell responses that are probably responsible for their control of HIV-1 infection 
(O’Connell et al, 2009, Migueles et al, 2002, Betts et al, 2006, Saez-Cirion, 2007, Migueles et al, 
2008, Hersperger et al, 2010, Buckheit et al, 2013). While HIV-1 specific CD8+ T cells in these 
subjects are not representative of the CD8+ T cell responses seen in the vast majority of HIV-
infected subjects, it is possible that successful therapeutic vaccination of these subjects will 
enhance CP HIV-specific CD8+ T cell responses to a similar level. We found that neither ingenol-
B at 100nM nor JQ1 individually inhibited the suppressive capacity of ES CD8+ T cells, but the 
combination of the two drugs had a modest inhibitory effect. While a difference in CD3 
downregulation kinetics could potentially, partially, explain the difference in the effects of 
bryostatin-1 and ingenol-B on HIV-specific CD8+ T cells, it does not explain the difference 
observed between ingenol-B and ingenol-B/JQ1 treated cells. 
 Besides CD3 modulation, we also looked at the expression levels of other cell surface 
markers such as CD8, annexin V and PD1, to determine if these could explain the difference in 
suppressive capacities of CD8+ T cells treated with either ingenol-B or its combination with JQ1. 
We found that ingenol-B alone and in combination with JQ1 does not significantly modulate CD8 
or PD1 expression on T cells. We also found that treatment with ingenol-B or ingenol-B/JQ1 
resulted in minimal cell death which confirms studies by Abreu et al (Abreu et al, 2014). 
 Our data are also consistent with a recent study that showed that treatment of peripheral 




the number of antigen specific CD8+ T cells that expressed perforin and CD107a (Clutton et al, 
2016). However, while the drug had no effect on the total number of CD8+ T cells that proliferated 
in response to antigen over a 5 day period, it inhibited the number of times antigen-specific CD8+ 
T cells proliferated (Clutton et al, 2016). Taken together, it is possible that while this drug may not 
have an effect on the short-term ability of HIV-specific CD8+ T cells to control infected CD4+ T 
cells, it could have a negative impact on the ability of HIV-specific CD8+ T cells to expand in 
vivo. Clinical trials will be needed to assess the effects of this drug alone, and in combination with 
JQ1, on HIV-specific CD8+ T cells in vivo. The effects of the drugs will likely be dose dependent 
and while we used concentrations of LRAs that have reversed latency in vitro, it is not clear that 
these are concentrations of ingenol-B and JQ1 that can be safely achieved in vivo. 
 In summary, our data suggest that drug combinations should be tested before being used in 
clinical trials because even LRAs that do not inhibit HIV-specific CD8+ T cell responses by 
themselves may have significant effects when they are used in combination with each other. 
Furthermore, while certain combinations of LRAs may be more potent at inducing viral 
transcription than individual LRAs, the advantages of this enhanced potency may be neutralized 





4 CHAPTER 3 
INTERFERON ALPHA ENHANCES NK CELL FUNCTION AND THE 
SUPPRESSIVE CAPACITY OF HIV-SPECIFIC CD8+ T CELLS 
4.1 ABSTRACT 
 Current shock-and-kill strategies for the eradication of the HIV-1 reservoir have resulted 
in blips of viremia but not in a decrease in the size of the latent reservoir in patients on suppressive 
antiretroviral therapy (ART). This discrepancy could potentially be explained by an inability of 
the immune system to kill HIV-1-infected cells following the reversal of latency. Furthermore, 
some studies have suggested that certain latency-reversing agents (LRAs) may inhibit CD8+T cell 
and natural killer (NK) cell responses. In this study, we tested the hypothesis that alpha interferon 
(IFN-α) could improve the function of NK cells from chronic progressors (CP) on ART. We show 
here that IFN-α treatment enhanced cytokine secretion, polyfunctionality, degranulation, and the 
cytotoxic potential of NK cells from healthy donors (HD) and CP. We also show that this cytokine 
enhanced the viral suppressive capacity of NK cells from HD and elite controllers or suppressors. 
Furthermore, IFN-α enhanced global CP CD8+ T cell cytokine responses and the suppressive 
capacity of ES CD8+ T cells. Our data suggest that IFN-α treatment may potentially be used as an 
immunomodulatory agent in HIV-1 cure strategies. 
 
4.2 INTRODUCTION 
 Attempts to cure HIV-1 have been unsuccessful due to the presence of latent HIV 




been proposed to meet this challenge, including the “shock-and-kill” strategy, where latency-
reversing agents (LRAs) are used to pharmacologically reverse latency in order to render formerly 
quiescent reservoirs susceptible to both antiretroviral therapy (ART) and the immune system (Cary 
and Peterlin, 2016, Marsden and Zack, 2015, Martin and Siliciano, 2016). However, while 
treatments with certain LRAs have resulted in viral blips, no trial has demonstrated changes in the 
size of the latent reservoir (Sogaard et al, 2015, Archin et al, 2012, Archin et al, 2014, Spivak et 
al, 2014, Rasmussen et al, 2014, Elliott et al, 2014, Elliott et al, 2015), owing perhaps to the 
dysfunctional state of potential effector cells. This awareness has drawn attention to the need to 
potentiate immune responses in order to efficiently eliminate reactivated reservoirs (Perreau et al, 
2017, Riley and Montaner, 2017). 
 As part of these efforts, there has been a lot of attention focused on CD8+ T cells. However, 
while these cells play a critical role in the control of HIV-1 replication, they also possess 
limitations. They are slower to respond to viral infections due to the timing of the adaptive immune 
response, they are susceptible to viral escape strategies such as HLA downregulation (Collins et 
al, 1998), and they are typically excluded from B cell follicles in lymph nodes (Folkvord et al, 
2005, Connick et al, 2007, Fukazawa et al, 2015), which can then serve as sanctuaries for sustained 
productive infection (Dahabieh et al, 2015). For these reasons, it is important to also analyze other 
immune effector cells capable of complementing CD8+ T cell effector function. Natural killer 
(NK) cells are ideal candidates for this role. They respond to viral infection without a need for 
clonal expansion, are thought to home to and control viral replication in lymph node sanctuaries 
(Huot et al, 2017), and are equipped to kill infected cells that evade CD8+ T cell elimination by 




 NK cell function can be augmented by various cytokines, including interleukin-15 (IL-15), 
IL-18, and IL-21, as well as type 1 interferons (IFNs) (Zwirner and Domaica, 2010). IL-15 in 
particular has recently been shown to enhance NK cell-mediated antiviral activity in humanized 
mice (Seay et al, 2015) and in vitro following latency reversal in CD4+ T cells from patients on 
ART (Garrido et al, 2018). In this study, we focused on alpha interferon (IFN-α) since it has been 
used clinically for the treatment of hepatitis C (Maughan and Ogbuagu, 2018). As a member of 
the type 1 IFN family, IFN-α helps create antiviral immune states that in turn help control the 
spread of viral infections (Odorizzi and Wherry, 2013). The efficiency of this IFN-mediated 
control, however, is principally dependent on the timing and concentration levels of IFN-α 
(Odorizzi and Wherry, 2013, Telenti, 2014). Specifically, in the SIV model of HIV-1 infection, 
type 1 IFNs ramp up the immune system and tip the scales in favor of an antiviral state that helps 
control infection spread in primary infection (Sandler et al, 2014). However, several studies have 
suggested that IFN-α also plays a role in the immune dysfunction seen in the chronic stages of 
HIV-1 infection (Hardy et al, 2013, Sedaghat et al, 2008). Therefore, to maximize the benefits of 
type 1 IFN (IFN-α) for NK cells, a fine line must be drawn in choosing a concentration and regimen 
that facilitates an antiviral response without causing excessive immune activation that triggers a 
transition away from that antiviral state. 
 While several studies have shown that IFN-α enhances NK cell cytokine secretion and 
cytotoxic responses in healthy donors (Ellis et al, 1989, Jewett et al, 1995, Tomescu et al, 2007, 
Tomescu et al, 2015) and, in a subset of HIV controllers (Tomescu et al, 2012), similar studies 
have not been performed with chronic progressor (CP) NK cells. We therefore sought to determine 
via in vitro assays, whether treatment of CP NK cells over short periods of time (termed a “pulse”) 




responses, without inhibiting general CD8+ T cell function. We also sought to determine whether 
similar treatments would enhance NK cell-mediated HIV-1 replication suppression in elite 
suppressor (ES) NK cells, again without inhibiting the HIV-specific suppressive capacities of 
CD8+ T cells. Our results suggest that IFN-α pulse therapy could be employed for enhancing NK 
cell effector function in HIV-1 cure strategies. 
 
4.3 METHODS 
4.3.1  Patients 
 
 Blood samples from HIV-negative and HIV-positive donors were obtained with written 
informed consent and subsequently handled in accordance with protocols approved by the Johns 
Hopkins University IRB. An elite suppressor (ES) refers to a patient who has maintained 
undetectable viral loads in the absence of ART (Blankson, 2010), while a chronic progressor (CP) 
refers to a patient who has maintained undetectable viral loads for more than a year on ART. 
Viremic progressors (VP) were patients who were not on ART and were viremic. VP1 had a CD4 
count of 192 cells/μl and a viral load of 7,250 copies/ml and VP2 had a CD4 count of 296 cells/μl 
and a viral load of 17,100 copies/ml. Healthy donors (HD) refer to HIV-negative individuals. 
4.3.2 NK cell cytokine secretion and degranulation assay 
 
 PBMCs were collected from donor whole blood after Ficoll-Paque Plus gradient 
centrifugation (GE Healthcare Life Sciences, Baltimore, MD). Next, NK cells were isolated from 
HD and CP PBMCs with NK cell-specific Miltenyi beads (Miltenyi Biotec, Gaithersburg, MD). 
The NK cell purity was generally in the range of 90%. Sample purity levels can be found in Figure 




supplemented with 10% fetal bovine serum [FBS], 1% Pen-Strep, and 10 U/ml IL-2) or various 
concentrations of IFN-α (2a) diluted in medium (1 U/ml to 200 U/ml; PBL Assay Science, 
Piscataway, NJ). At the end of IFN-α pulses, cells were washed three times and cocultured for 4 
hours at a 1:1 effector/target ratio with K562 cells to assess the relative effect of IFN-α on NK 
degranulation and cytokine production. NK cells treated with IFN-α were also washed and cultured 
alone to determine any nonspecific effects of IFN-α on NK cell function in the absence of target 
cell stimulation. Untreated NK cells were also cultured alone as a negative control. All cultures 
were performed in medium supplemented with protein transport inhibitors (Golgi Plug, 1 μg/ml; 
Golgi Stop, 0.7 μg/ml; CD49d, 1 μg/ml [BD Bioscience, San Diego, CA]), as well as an antibody 
to CD107a (FITC; BD Bioscience, clone H4A3). K562 cells were used because their lack of MHC-
I surface expression makes them targets for NK cells. At the end of the 4 hours, the cells were 
washed three times and stained for surface markers: CD3 (PB; BD Bioscience, clone UCHT1), 
CD16 (PerCPcy5.5; BD Bioscience, clone 3G8), and CD56 (APCH7 [BioLegend, San Diego, 
CA], clone HCD56). Cells were also probed for the production of cytokines via intracellular 










Figure 23. Representative plot of percent purity of effector cells prior to each experimental assay run. NK cells and CD8+ T 
cells employed as effectors in each experiment were obtained by cell specific Miltenyi isolation kits, with an average 90% cell 
purity. 
 
4.3.3 NK cell cytotoxicity assay 
 
The robust production of cytokines by an effector cell may not always correlate with cytotoxicity. 
Therefore, to assess NK cytotoxicity, we used the following assay adapted from Derby et al. 
(2001). Briefly, effector NK cells from CP PBMCs were isolated as previously described. CD4+ T 
cells were also isolated from a portion of patients PBMCs. Next, NK cells were pulsed as described 
above with media for a baseline control or media with 100 or 200 U of IFN-α. CD4+ T cells, 
however, were pulsed with medium only. To distinguish between effector and target cells, K562 
cells were labeled with 2.5 μM of CFSE (carboxyfluorescein succinimidyl ester) at 106 cells/ml of 
CFSE with gentle vortexing. CFSE was then quenched with lukewarm FBS. The K562 cells were 
then washed three times and cocultured for 4 hours with pretreated, washed, NK cells at a 5:1 
effector/target ratio (targets at 100,000 cells per well in 96-well flat bottom plates). Killing was 
determined by flow cytometry as CFSE-positive cells that co-expressed 7AAD and annexin V. To 
affirm that any cytotoxicity observed was NK cell specific, CFSE-labeled K562s were also 
cultured with CD4+ T cells at the same effector/target ratios. Any background death observed in 




4.3.4 NK cell and CD8+ T cell suppression assay 
 
 PBMCs were isolated from HD and ES blood as described above. In ES these PBMCs were 
divided into two sets: from one set CD8+ T cells were isolated (by positive selection) and from 
the other NK cells were isolated by negative selection. CD4+ T cells were then isolated, by 
negative selection, from the flow-through of the CD8+ T cell isolation. In HD, PBMCs were split 
into two sets with one set used for NK cell isolation and the other for CD4+ T cell isolation. All 
cells were isolated with cell type-specific Miltenyi beads. As with NK cells, CD8+ T cell purity 
levels were generally in the 90% range (Figure 23). Effector cells (CD8+ T cells or NK cells) were 
then pulsed with either medium or various concentrations of IFN-α as described above. Next, target 
cells (bulk CD4+ T cells) were infected by spinoculation at 30 ng of HIV-1 p24/100,000 cells with 
a pseudotype virus (HIV-1-NL4-3ΔEnv–GFP) for 2 hours at 1,200 × g and 37°C. HIV-1-NL4-
3ΔEnv–GFP is a lab strain of HIV-1 that has env replaced with gfp. At the end of the cytokine 
pulse, effector cells were washed three times and co-cultured over 72 hours with infected CD4+ T 
cells at an effector/target ratio of 1:1. The percent GFP expression, as measured by flow cytometry, 
was subsequently used to assess the percent viral suppression according to the following formula: 
[1 – (%GFP + CD4+ T cells cultured with effectors)/(%GFP + CD4+ T cells without effectors)] × 
100. 
 The median percentage of GFP infection in CD4+ T cells that were cultured in medium 
alone was 6% for HD and 13% for ES. In VP, an average of 6% GFP in infected CD4+ T cells 
was seen in the two subjects studied. For transwell experiments, 1 million infected CD4+ T cells 
were cultured at the bottom of 12-well transwell plates, while 1 million CD8+ T cell effectors were 
cultured in the transwell inserts. Infected CD4+ T cells were cultured alone to determine the 




to determine the effect of direct contact of the effector and target cells. Cultures were maintained 
for 3 days, and viral replication suppression was measured as a percentage of GFP expression via 
flow cytometry. 
4.3.5 CD8+ T cell cytokine secretion and degranulation assay 
 
 To ensure that the concentrations of IFN-α used in this assay to enhance NK cell function 
did not impair the cytokine-producing abilities of patient CD8+ T cells, general CD8+ T cell 
cytokine production was also assessed in CP. Specifically, CD8+ T cells were isolated from CP 
PBMCs (Miltenyi Biotec) and pulsed with either medium or various concentrations of IFN-α 
diluted in medium as before. At the end of this pulse, cells were washed three times and stimulated 
for 4 hours with either medium alone (baseline control) or anti-CD3 MAb at 1 μg/ml (BD 
Bioscience), all in the presence of protein transport inhibitors, as well as an antibody to CD107a. 
The cells were then washed and stained for surface markers CD3 (PB, BD Bioscience, clone 
UCHT1) and CD8 (APCH7, BD Biosciences, clone SK1), as well as cytokine production via 
intracellular staining for IFN-γ (PECy7, BioLegend, clone B27) and MIP-1β (PE, BD Bioscience, 
clone D21-1351). 
4.3.6 CD8+ T cell in IFN-γ ELISpot assays  
 
 Beyond general CD8+ T cell function, we also sought to determine whether IFN-α 
treatment of CP CD8+ T cells inhibited their ability to release the type II interferon (IFN-γ) in an 
HIV-specific manner. We performed IFN-γ-specific ELISpot assays as previously described 
(Pohlmeyer et al, 2018), following pretreatment of patient cells with the candidate type I IFN (IFN-
α 2a). Specifically, PBMCs were isolated from CP whole blood, seeded at 250,000 cells per well, 
and treated for 6 hours with either medium as a baseline control or 100 U of IFN-α. Cells were 




antibodies (Mabtech, Human IFN-γ ELISpot Plus), and stimulated for 18 hours with either medium 
alone or 10 μg/ml of overlapping consensus B Gag and Nef peptides (NIH AIDS Reagent 
Program). The plate was then processed according to the manufacturer’s protocol and read, 
blinded, by an independent investigator using an automated reading system. 
4.3.7 Statistics 
 
 Statistics were generated by GraphPad Prism 7. For each set of experiments, the one-way 
repeated-measures analysis of variance (ANOVA) was used to assess statistical significance, and 
levels of significance were parsed out with the ensuing P value demarcations as follows: 
ns, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; and ****, P < 0.0001. To account for any 
violations in sphericity, the Geisser-Greenhouse correction was used during data analysis. Finally, 
in all cases, a Dunnett’s multiple-comparison test was used to assess variations of treatment groups 
from no-treatment baseline controls. Standard deviations were used to determine the variations 
from the mean within treatment groups. 
 
4.4 RESULTS 
4.4.1 IFN-α enhances degranulation and cytokine production in CP NK cells 
 
 The goal of this study was to determine whether short treatments of IFN-α could be used 
to enhance CP NK cell effector function without incapacitating the effector functions of CD8+ T 
cells. To answer this question, assays measuring NK cell degranulation and cytokine production 
were used. The presence of residual intracellular drugs prevents effective superinfection of CP 
CD4+ T cells. We therefore assessed the effects of IFN-α on CP NK cell function by measuring 
the response of these cells to K562 cells. Briefly, isolated CP NK cells were pulsed with media 




targets at a 1:1 effector/target ratio in the presence of a CD107a antibody and protein transport 
inhibitors. NK cells from healthy donors (HD) were treated in a similar fashion as a means of 
comparison to results from CP-treated NK cells. The percent expression of various cytokines was 
then assessed via flow cytometry. Relative to untreated NK cells, there was little to no nonspecific 
production of cytokines from NK cells treated with IFN-α and cultured in the absence of target 
cells (data not shown). However, in the presence of targets, IFN-α treatment significantly increased 
the cytokine-producing capacity of HD NK cells. As shown in Figure 24A, IFN-α-treated HD NK 
cells, relative to baseline, showed a marked increase in CD107a degranulation (P < 0.0008). IFN-
α treatment also significantly increased the production of MIP-1β (Figure 24B, P < 0.0006) and 
IFN-γ (Figure 24C, P < 0.004). CP NK cells also yielded significant amounts of CD107a (Figure 
24D, P < 0.001), MIP-1β (Figure 24E, P < 0.0001), and IFN-γ (Figure 24F, P < 0.002), with 
stimulation of K562 cells following IFN-α pulses. 
 More importantly, not only were individual cytokine secretion and degranulation profiles 
of IFN-α-treated NK cells enhanced, but their polyfunctional profiles were enhanced as well. As 
shown in Figure 25, pretreatment of CP NK cells with IFN-α significantly increased the co-
expression of CD107a and MIP-1β (Figure 25A, P < 0.002), CD107a and IFN-γ (Figure 
25B, P < 0.005), and MIP-1β and IFN-γ (Figure 25C, P < 0.004). In addition, there was also 
enhanced co-expression of all three proteins in CP (Figure 25D, P < 0.0007) and HD (Figure 
25E, P < 0.0008). There was no significant difference in the percentage of polyfunctional NK cell 
responses between HD and CP. We also assessed whether longer treatments with IFN-α would 
further increase CP NK cell polyfunctionality and found that while 6 hours of treatment resulted 
in a more potent response than one hour, no added benefit was seen with 18 or 24 hours of pre-




4.4.2 IFN-α significantly enhances CP NK cytotoxicity 
 
 In assessing whether IFN-α treatment actually enhanced CP NK cell cytotoxic responses 
against target cells, we labeled K562 cells with CFSE and used that as a means of detecting cell 
death in the target cell population within an effector-target co-culture. As described in Materials 
and Methods, death was assessed via flow cytometry as CFSE+ cells that were double positive for 
7-aminoactinomycin D (7AAD) and annexin V (Figure 27). Of the six CP studied at the 5:1 
effector/target ratio, brief IFN-α treatments significantly enhanced CP NK cell cytotoxicity with 
an approximate net difference in death of 20% in IFN-α-treated NK cells relative to untreated 
baseline NK cells (Figure 28, P = 0.0004 for 100 U and 0.0001 for 200 U). To ensure that cytotoxic 
responses in these experiments were NK cell specific, co-culture of K562 cells with CD4+ T cells 
(as effectors) was performed simultaneously with co-cultures of K562 cells with NK cells. Death 








Figure 24. IFN-α enhances degranulation and cytokine production in HD and CP NK cells. NK cells from 8 HD and 8 CP 
were treated with either medium alone (NT baseline) or various concentrations of IFN-α for 6 h, washed, and then cocultured for 
4 h with target K562 cells or medium alone (NK only) in the presence of a CD107a antibody and protein transport inhibitors. 
Enhancement of degranulation and cytokine production was subsequently studied by flow cytometry following surface and 




(E) MIP-1β in CP; (F) IFN-γ in CP. Triplicates were performed for each patient with error bars representing standard deviation 
from mean within treatment groups. One-way repeated-measures ANOVA was used to determine difference between baseline and 













Figure 25. IFN-α enhances HD and CP NK cell polyfunctionality. NK cells from 8 HD and 5 to 8 CP were pulsed with either 
medium (NT baseline) or various concentrations of IFN-α for 6 h, washed, and then cultured alone (NK only) or for 4 h with target 
K562 cells in the presence of antibodies to CD107a and protein transport inhibitors. The assessment of enhancement of 
degranulation, bi- and trifunctional protein production was subsequently studied via flow cytometry following surface and 
intracellular staining. In our analysis, bulk CP NK cells were probed for the simultaneous production of either CD107a and MIP-
1β (A), CD107a and IFN-γ (B), and MIP-1β and IFN-γ (C). Bulk CP (D) and HD (E) NK cells were then also probed for the 
simultaneous production of CD107a, MIP-1β, and IFN-γ. In all experiments, triplicates were performed for each subject, with error 
bars representing standard deviations from mean within treatment groups. One-way repeated-measures ANOVA was used to 
determine the differences between baseline and specific treatments. Asterisks indicate differences from a no-treatment baseline 





Figure 26. Extended incubation beyond 6 hours of NK cells with IFN-α does not further enhance their polyfunctional 
responses. NK cells were isolated from 4 CPs and treated with either media alone (NT baseline), or a single concentration of IFN-
α (100u) over either 1, 6 18 or 24 hours. At the end of the incubation, cells were washed, then cultured alone (NK only) or for 4 
hours with target K562 cells in the presence of antibodies to CD107a and protein transport inhibitors. The assessment of 
polyfunctional protein production was subsequently studied via flow cytometry following surface and intracellular staining. In 
analysis, bulk NK cells were probed for the simultaneous production of CD107a, MIP1-β and IFN-γ. In all experiments, triplicates 
were performed for each subject with error bars representing standard deviation from mean within treatment groups. One way 
repeated measures ANOVA was used to determine difference between baseline and specific treatments. Stars above show 
differences from no treatment baseline control with * p<0.0001. 
 
 
Figure 27. Representative flow plot of NK:K562 cytotoxicity assay. NK cells (or CD4+ T cells) were isolated from 6 CP and 
treated with either media alone (NT baseline), or varying concentrations of IFN-α for 6 hours, washed, then co-cultured for 4 hours 
at a 5:1 effector:target ratio with CFSE labelled target K562 cells. Cell death was then assessed by the co-expression of 7AAD and 
Annexin V on K562 cells. From the left, cell death assessment in: CFSE positive K562 cells without NK effectors, CFSE positive 
K562 cells co-cultured with untreated NK cell effectors and CFSE positive K562 cells co-cultured with effector NK cells treated a 





Figure 28. IFN-α enhances CP NK cell cytotoxicity. NK cells and CD4+ T cells were isolated from 6 CP and treated with either 
medium alone (NT baseline) or various concentrations of IFN-α for 6 hours, washed, and then co-cultured for 4 hours with CFSE-
labeled target K562 cells. Cell death was assessed based on the co-expression of 7AAD and annexin V on K562 cells. Experiments 
were conducted at a 5:1 effector/target ratio. In each experiment, CD4+ T cell effectors (CD4-E) were used at the same 
effector/target ratio as a control to affirm NK-specific cytotoxicity. Asterisks indicate differences from a no-treatment baseline 
control (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). Duplicates were performed for each patient with error bars 
representing standard deviations from the mean within treatment groups. One-way repeated-measures ANOVA was used to 
determine the difference between baseline and specific treatments 
 
4.4.3 IFN-α enhances the suppressive capacity of HD and ES NK cells 
 
 To determine whether IFN-α treatment of NK cells could impact their control of HIV-1 
replication in vitro, we assessed the suppressive capacities of HD and ES NK cells with or without 
IFN-α treatment. CP were not used for these experiments, since the presence of residual 
antiretroviral drugs in CD4+ T cells from these patients prevents efficient superinfection of their 
cells in vitro.  
 NK cells from 8 HD and 10 ES were treated for 6 hours with either medium alone (baseline 
control) or various concentrations of IFN-α. The cytokine was then washed off, and the NK cells 




Materials and Methods. Suppression, defined as a reduction in the percentage of target cells 
expressing GFP, was calculated following flow cytometry, with infected targets cultured without 
effectors being used to normalize the percent infection. As expected, not all HD NK cells were 
able to suppress viremia at baseline. However, some concentrations of IFN-α, particularly 50 U 
and higher, significantly improved NK cell suppression capacity in these subjects (Figure 
29A, P < 0.04). A higher baseline level of suppression was seen with ES NK cells, and this was 
further enhanced after treatment with 10 U or higher of IFN-α (Figure 29B, P < 0.04). 
4.4.4 IFN-α treatment enhances degranulation and the cytokine producing capacity of CP 
CD8+ T cells 
 
 Having shown that IFN-α significantly enhanced NK cell polyfunctionality and HIV-1 
suppressive capacity, we next sought to determine whether this cytokine had inhibitory effects on 
CD8+ T cell responses, as has been previously shown in untreated HIV-1 infection. To answer this 
question, assays measuring CD8+ T cell cytokine production and degranulation after treatment 
with anti-CD3 monoclonal antibody (MAb) were employed. Figure 30 summarizes results for 
CD8+ T cells. Specifically, IFN-α treatment increased degranulation in CD8+ T cells following 
stimulation, as measured by CD107a (Figure 30A, P < 0.0008). MIP-1β production was also 
similarly increased after IFN-α treatment relative to untreated, stimulated, CD8+ T cells (Figure 
30B, P < 0.04). In addition, CD8+ T cells from CP treated with IFN-α also showed significant 
increases in IFN-γ production (Figure 30C, P < 0.02). Stimulation of CD8+ T cells with IFN-α 








Figure 29. IFN-α enhances the suppressive capacity of HD and ES NK cells. NK cells from 8 HD (A) and 10 ES (B) were 
treated with either medium alone (NT) or various concentrations of IFN-α for 6 hours, washed, and then co-cultured over 3 days at 
a 1:1 ratio with autologous CD4+ T cells infected with a GFP-tagged pseudotype lab strain of HIV-1. Viral replication suppression 
was measured as a percentage of GFP expression via flow cytometry. Triplicates were performed for each patient, with error bars 
representing the standard deviation, from means within treatment groups. One-way repeated-measures ANOVA was used to 
determine the difference between baseline and specific treatment groups. Asterisks indicate the differences from a no-treatment 








4.4.5 IFN-α treatment does not inhibit CP HIV specific CD8+ T cell IFN-γ responses 
 
 Having demonstrated that IFN-α treatment enhanced global CP CD8+ T cell responses, we 
next analyzed its effect on CP HIV-specific CD8+ T cells responses. To do this, we performed 
enzyme-linked immunospot (ELISpot) studies using peripheral blood mononuclear cells (PBMCs) 
from CP pulsed with a 100U dose of IFN-α for 6 hours prior to stimulation with overlapping Gag 
and Nef peptides. As shown in Figure 31A, there was minimal nonspecific production of IFN-γ 
with IFN-α treatment. Furthermore, pretreatment of PBMCs with IFN-α had no effect on the 
number of IFN-γ-producing cells following stimulation with Gag and Nef peptides. 
4.4.6 IFN-α enhances the suppressive capacity of ES CD8+ T cells 
 
 We next analyzed the effect of IFN-α on the suppressive capacity of ES CD8+ T cells. 
Similar to the suppression experiments performed with ES NK cells, ES CD8+ T cells were 
isolated from eight ES and pulsed with either medium alone (baseline control) or various 
concentrations of IFN-α for 6 hours. The cells were then washed and co-cultured at a 1:1 
effector/target ratio with autologous CD4+ T cells infected with a green fluorescent protein (GFP)-
tagged pseudotype lab strain of HIV-1. The culture was maintained over 3 days, and suppression, 
defined as a reduction in the percentage of target cells expressing GFP, was measured by flow 
cytometry. Similar to the suppression observed with NK cells, each IFN-α treatment significantly 
improved the suppressive capacities of CD8+ T cells (Figure 31B, P < 0.03). In ES22 we 
demonstrated that suppression was contact dependent since separating the CD8+ T cells from the 
target cells with a transwell abrogated the inhibitory response (Figure 32). In summary, IFN-α did 






4.4.7 IFN-α enhances the suppressive capacity of VP CD8+ T cells 
 
 Because we were unable to determine the effect of IFN-α on the suppressive capacity of 
CP CD8+ T cells due to the presence of residual ART, we looked at the effect on two viremic 
subjects. In both cases, we saw enhanced suppressive capacity when CD8+ T cells were 







Figure 30. IFN-α treatment enhances CP CD8+ T cell degranulation and cytokine production. CD8+ T cells from 6 to 8 CP 
were pulsed with either medium alone (baseline) or various concentrations of IFN-α for 6 hours, washed, and then cultured for 4 
hours in the presence of a CD107a antibody and protein transport inhibitors. Enhancement of degranulation and cytokine production 
was subsequently studied via flow cytometry following surface and intracellular staining. Specifically, the cells were either not 
treated but stimulated (NT) or treated with various units of IFN-α and stimulated with anti-CD3 MAb. (A) CD107a degranulation; 
(B) MIP-1β; (C) IFN-γ. Triplicates were performed for each patient, with error bars representing the standard deviations from the 




specific treatments. Asterisks indicate the differences from a no-treatment baseline control (*, P < 0.05; **, P < 0.01; 
***, P < 0.001; ****, P < 0.0001). 
 
 
Figure 31. IFN-α enhances the suppressive capacity of VP and ES CD8+ T cells without inhibiting HIV-specific IFN-γ 
responses of CP CD8+ T cells. (A) PBMCs from 8 CP were pulsed with either medium alone (baseline) or 100 U/ml of IFN-α for 
6 h, washed, and then cultured for 18 h with or without CMV, Gag, or Nef peptides. An IFN-γ ELISpot assay was then used to 
assess the effect of IFN-α treatment on the production of IFN-γ by CP CD8+ T cells. Duplicates were performed for each patient, 
with error bars representing the standard deviations from the mean within treatment groups; saturated responses (CMV) were not 
included in data. One-way repeated-measures ANOVA was used to determine the difference between baseline and 100-U 




washed, and then cocultured over 3 days at a 1:1 ratio with autologous CD4+ T cells infected with a GFP-tagged pseudotyped lab 
strain of HIV-1. Viral replication suppression was measured as a percentage of GFP expression via flow cytometry. Triplicates 
were performed for each patient, with error bars representing the standard deviations from the mean within treatment groups. One-
way repeated-measures ANOVA was used to determine the difference between baseline and specific treatments. Asterisks indicate 
the differences from a no-treatment baseline control *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. (C) CD8+ T cells 
from 2 VP were pulsed with either medium alone (NT) or 100 U/ml of IFN-α for 6 h, washed, and then cocultured over 3 days at 
a 1:1 ratio with autologous CD4+ T cells infected with a GFP-tagged pseudotyped lab strain of HIV-1. Viral replication suppression 
was measured as a percentage of GFP expression via flow cytometry. Triplicates were performed for each patient. 
 
 
Figure 32. Viral suppression in ES CD8+ T cells is contact dependent. CD8+ T cells from an ES (ES22) were pulsed with 
either media alone (NT) or 100u of IFN-α for 6 hours. Cells were then washed, and co-cultured over 3 days at a 1:1 
effector:target ratio (at 1 million cells for either effectors or targets) with autologous CD4+ T cells infected with a GFP tagged 
pseudotyped lab strain of HIV-1. Effector target cultures were either done together, or in transwells (TW) with target cells in the 
bottom of the plate and effectors in transwell inserts. Infected CD4+ T cells were also cultured alone for the purpose of 










 Several clinical trials with LRAs have not resulted in reductions in the size of the latent 
reservoir (Sogaard et al, 2015, Archin et al, 2012, Archin et al, 2014, Spivak et al, 2014, Rasmussen 
et al, 2014, Elliott et al, 2014, Elliott et al, 2015). One possible explanation for this might be that 
effector immune cells critical to the “killing” aspect of the strategy are inefficient. Several studies 
have also shown that some LRAs inhibit NK cell (Garrido et al, 2016, Pace et al, 2016) and 
CD8+ T cell (Jones et al, 2014, Walker-Sperling et al, 2016, Kwaa et al, 2017) function. To address 
these concerns, efforts are now being directed at enhancing immune effector function for the 
control of HIV (Perreau et al, 2017, Riley and Montaner, 2017). While many of these are directed 
toward CD8+ T cells, NK cells would be important effector cells to consider for the purpose of 
complementing CD8+ T cell function in HIV control (Scully and Alter, 2016, Carrington and 
Alter, 2012). In the present study, we confirm prior studies that showed that pre-treatment of NK 
cells with IFN-α enhances cytokine secretion, viral suppression, and the cytotoxic potential of HD 
(Ellis et al, 1989, Jewett and Bonavida, 1995, Tomescu et al, 2007, Tomescu et al, 2015) and ES 
NK (Tomescu et al, 2012) cells against target K562 cells. While Portales et al. (2003) showed an 
enhancement in NK cell perforin and granzyme A expression in patients who were treated with 
pegylated IFN-α2b, this is to our knowledge the first demonstration of IFN-α directly enhancing 
cytokine secretion and the killing capacity of CP NK cells. IFN-α pulses also enhanced the ability 
of HD and ES NK cells to suppress HIV-1 replication in autologous CD4+ T cells. While we were 
not able to study this particular function in CP NK cells, the fact that CP and HD NK cells had 
similar levels of degranulation and cytokine production in response to IFN-α following stimulation 




Furthermore, in addition to studies showing improvement in direct NK cell cytotoxic activity, 
Tomescu et al. showed that IFN-α enhances NK cell-mediated antibody-dependent cell-mediated 
cytotoxicity (Tomescu et al, 2017). Thus, it appears that this cytokine enhances multiple facets of 
NK cell function. 
 Betts et al. demonstrated that the polyfunctionality of CD8+ T cells was a major correlate 
of HIV-specific immunity (Betts et al, 2006). These results have since been corroborated not only 
in CD8+ T cell studies (Migueles and Connors, 2015) but also in NK cell studies. Specifically, in 
two separate reports, Boulet et al. (2010) and Kamya et al. (2011) demonstrate that HIV+ patients 
with the HLA-Bw4 ligand and its cognate NK receptor, KIR3DL1, had more polyfunctional NK 
cells, which accordingly contributed to slower disease progression. We show here for the first time 
that IFN-α enhances polyfunctionality in CP NK cells to a level that is similar to that seen in HD 
NK cells. This enhanced NK cell polyfunctionality may lead to better control of HIV-1 replication 
in shock-and-kill strategies. 
 We minimized our IFN-α pre-incubation exposure for two reasons. The first was to 
determine the feasibility of efficiently enhancing NK cell effector function within the narrow time 
frame that effector cells have for the elimination of infected CD4+ T cells prior to the release of 
virions after latency reversal (Walker-Sperling et al, 2015). We show here that 6 hours of pre-
incubation with IFN-α was as effective as 24 hours. Our finding that this short window of exposure 
was sufficient to efficiently and significantly enhance the suppressive, cytotoxic, and 
polyfunctional responses of NK cells in CP is exciting and suggests that it may be possible to 
optimize NK cell activity while avoiding IFN-α-mediated immune exhaustion in both NK cells 




 Several studies have suggested that type I IFNs can lead to apoptosis of memory T cells in 
mice, thereby compromising the adaptive immune response (Welsh et al, 2012, McNally et al, 
2001, Bahl et al, 2006). Other studies have shown that IFN-α induces immune activation of 
CD8+ T cells from HIV-positive subjects in vitro (Rodriguez et al, 2006, Hua et al, 2014) and in 
vivo (Manion et al, 2012). Furthermore, studies in humanized mice have shown that blocking the 
IFN-α/β receptor enhances HIV-specific immune responses (Cheng et al, 2017, Zhen et al, 2016). 
In contrast to these studies, we show here for the first time that pre-treatment with IFN-α for a 
limited period of time did not inhibit HIV-specific CD8+ T cell IFN-γ responses and resulted in a 
moderate enhancement of global CD8+ T cell responses in CP. Furthermore, there was also a 
modest enhancement in HIV-suppressive CD8+ T cell responses in ES and in two VP. These 
responses are not due to non-specific activation of CD8+ T cells by IFN-α; instead, we show here 
that the suppression was contact dependent, which is consistent with our prior studies (Shan et al, 
2012, Walker-Sperling et al, 2014, Veenhuis et al, 2018). However, further studies will be needed 
to definitively determine whether this is due to direct cytotoxic activity, as has been previously 
demonstrated for IFN-α-treated NK cells (Tomescu et al, 2015). If this enhanced HIV-specific 
CD8+ T cell response is confirmed with in vivo studies, it would suggest that pulse therapy with 
IFN-α could enhance both innate and adaptive antiviral immune responses in CP. A clinical trial 
has already shown that treatment with IFN-α prolongs the time to viral rebound following the 
cessation of ART (Azzoni et al, 2013). In another study, NK cell activation was associated with a 
decline in cell-associated HIV-1 DNA in HIV-1/HCV-co-infected subjects treated with pegylated 
IFN-α and ribavirin (Hua et al, 2017). While a recent study in SIV-infected monkeys on ART 
suggested that pegylated IFN-α2a treatment did not significantly affect the size of the viral 




conjunction with this immunomodulatory agent. An exciting new direction, given these data, 
would be the coupling of short course IFN-α therapy with LRAs in shock-and-kill trials with the 
goal of eliminating reactivated reservoirs without exacerbating pre-existing immune exhaustion 







































5 CONCLUSIONS AND FUTURE DIRECTIONS 
 It has now been decades since its discovery, yet viral latency continues to stand as a barrier 
towards persistent efforts towards a cure to HIV/AIDS. The goal of this thesis work, therefore, 
was to gather novel data that would contribute to the growing body of knowledge on the nature of 
the latent reservoir and how we might combat it. 
 In our first chapter, we look to define the size of the inducible latent reservoir in ES relative 
to CP as a (possible) guide to what a goal of inducible reservoir frequency could be in order to 
attain a functional cure. Specifically, we employ the newly described IPDA and make two 
important observations. First, our findings from a cohort of ES and CP demonstrates that the 
frequency of both total and intact proviruses in ES is significantly smaller than in CP, but that the 
proportion of intact to total proviruses does not significantly differ between the two patient groups. 
If this ratio had been significantly smaller in ES, it might have suggested that ES achieve elite 
control possibly due to a disproportionate infection with defective viruses (Calugi et al, 2006, 
Kirchoff et al, 1995, Miura et al, 2010). That there was no difference, however, reinforces data 
from many studies (Blankson et al, 2007, Lamine et al, 2007, Bailey et al, 2008, Julg et al, 2010, 
Buckheit et al, 2012, Salgado et al, 2014) that show that while the afore mentioned concern may 
be true in some ES, it is not true for all. The second important finding we make is that although 
most ES do have smaller inducible reservoirs (Salgado et al, 2014, Mendoza et al, 2012, Noel et 
al, 2016) a small latent reservoir may not be required for either elite control or a functional cure. 
We conclude this from our observation of one patient, ES24, who had the largest frequency of 
intact proviruses relative to all other patients studied, yet had at the time of study, maintained 
control in the absence of ART. Overall therefore, even though this study is limited by a small 
sample size, it sheds important light not only on our current understanding of elite control as it 




completely decipher the phenomenon of elite control in order to improve our chances of obtaining 
a functional cure to HIV/AIDS, for all.  
 After quantifying the reservoir via IPDA in ES, we move on to chapter 2 to assess how 
drugs targeted at reactivating the viral reservoir might impact immune effector cell function. This 
is an important topic to focus on given that shock-and-kill remains the most widely clinically tested 
attempt at eliminating the latent reservoir despite data suggesting that drug combinations that 
successfully and efficiently reverse latency in vitro might simultaneously adversely impact 
immune effector cell function (Pace et al, 2016, Garrido et al, 2016, Akimova et al, 2012, Jones et 
al, 2014, Walker-Sperling et al, 2016, Clutton et al, 2016). Using in vitro studies, we specifically 
focused on ingenol-B and its combination with other LRAs to determine its effect on the 
suppressive capacity of ES CD8+ T cells. After studying an array of individuals (HD, ES and CP), 
we determined that this drug did not adversely affect HIV suppressive function of ES CD8+ T 
cells except when combined, at higher doses, with the bromodomain inhibitor JQ1. Thus far, a 
clinical trial using a derivative of ingenol (ingenol mebutate) has demonstrated that this active 
ingredient as part of a topical treatment for actinic keratosis, disrupted latent HIV in the skin tissue 
microenvironment, and achieved this without excessive immune activation or harm to immune 
cells (Jiang et al, 2019). While this corroborates our in vitro findings, it is a single trial with a 
single drug, locally administered and the concern from this work rests in combining ingenol with 
other LRAs. As such, as we strive to reverse latency and potentially eliminate inducible reservoirs 
in an attempt at a cure, the need for caution in balancing drug dosing and drug combination choices 





Currently, the advent of effective ART currently enables HIV infected individuals to live relatively 
normal lives. Yet the fact remains that given a choice, a cure is preferred to taking a pill a day, for 
life. Furthermore, not all patients can adhere to the medication regimen (due to health or other 
socio-economic reasons) and taking a pill every day for life can also have adverse side effects on 
individuals. For this reason, a cure (even a functional one) is necessary (Deeks et al, 2016), and 
yet data suggest that untreated HIV+ individuals unable to control infection fail to do so due to 
several factors including impaired cytokine production and/cytotoxic effector cell function. As 
such, the success of cure agendas including that of shock-and-kill will probably depend on 
enhancing patient effector cell function (Perreau et al, 2017, Riley and Montaner, 2017). 
 In the final chapter of this work, we demonstrate the ability of short-course alpha interferon 
(IFN-α) treatments to effectively enhance such effector functions in chronic progressor NK cells 
without inhibiting general CD8+ T cell function. These results point to the possibility of exploring 
such short-course IFN-α treatments for the enhancement of effector cell function in HIV+ patients 
in future cure strategies. While much of this work involved the use of an X4-tropic virus, data 
suggest that the majority of patients are first infected with an R5-tropic virus that then evolves into 
an X4-tropic infection (Weinberger and Perelson, 2011). Furthermore, the viruses employed were 
mainly single round pseudotyped reporter viruses with the absence of envelope precluding 
opportunities for studies on other aspects of NK cell function namely antibody dependent cellular 
cytotoxicity or ADCC. In one trial using IFN-α as an immunotherapy to treat CP (Azzoni et al, 
2013), findings from ex-vivo studies showed that genes associated with ADCC were identified in 
IFN-α responders and absent in non-responders (Papasavvas et al, 2019). Given this data, an 
important future direction would be to repeat these studies (with a possible cocktail of cytokines) 




neutralizing and non-neutralizing antibodies. Since broadly neutralizing antibodies and NK cells 
are gradually gaining renewed traction in the HIV cure agenda arena, the findings from these 
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